Protocol CL -P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
This confidential information about the investigational product is provided for the exclusive 
use of investigators of this product and is subject to recall at any time. The information in this 
document may not be disclosed unless federal or state law or regulations require such disclosure. Subject to the foregoing, this i nformation may be disclosed only to those persons 
involved in  the study who have a need to know, with the obligation not to further disseminate 
this information . 
O
 ctober 2 6, 2020 A Phase 1, Open -Label, 3 -Period, Randomized,  
Crossover Pharmacokinetic Study t o Ev aluate the 
Steady -State Pharmacokinetics of 5 m g and 10 mg 
Corplex™ Donepezil Transdermal Delivery Systems 
Compared to 1 0 mg Oral A dministration of A ricept® in 
Healthy Volunt eers
Protocol No: CL -P-20003 
Original Protocol dated: October 2, 2020 
Amendment #1 dated: 26Oct2020 
NCT - 04617782
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 4 of 78  October 2 6, 2020 
 TABLE OF CONTENTS  
LIST OF ABBREVIATIONS  ...................................................................................................... 7 
PROTOCOL SYNOPSIS  ............................................................................................................. 9 
1. SCHEDULE OF  EVENTS  ................................................................................................. 25 
2. TREATMENT PHASE SCHEMATIC  ............................................................................. 29 
3. BACKGROUND ................................................................................................................. 30 
3.1. Alzheimer’s Disease (AD)  ............................................................................................ 30 
3.2. Donepezil  ...................................................................................................................... 30 
4. OVERVIEW OF CLINICAL STUDIES  .......................................................................... 30 
5. STUDY RATIONALE  ........................................................................................................ 33 
6. STUDY OBJECTIVES  ....................................................................................................... 33 
6.1. Primary Objective  ......................................................................................................... 33 
6.2. Secondary Objectives .................................................................................................... 33 
6.3. Safety Objective  ............................................................................................................ 33 
7. INVESTIGATIONAL PLAN ............................................................................................ 33 
7.1. Study Design ................................................................................................................. 33 
7.2. Study Duration .............................................................................................................. 35 
8. SUBJECT SELECTION  .................................................................................................... 35 
8.1. Number of Subjects....................................................................................................... 35 
8.2. Study Population ........................................................................................................... 35 
8.2.1.  Inclusion Criteria ................................................................................................................... 35 
8.2.2.  Exclusion Criteria .................................................................................................................. 36 
9. STUDY TREATMENTS  .................................................................................................... 39 
9.1. Study Drug Treatments ................................................................................................. 39 
9.2. Treatment Assignment  .................................................................................................. 41 
9.3. Blinding......................................................................................................................... 41 
9.4. Compliance ................................................................................................................... 41 
10. STUDY PROCEDURES  ................................................................................................ 42 
10.1.  Screening Procedures .................................................................................................... 42 
10.2.  Check -In Procedures (Day -1) ...................................................................................... 43 
10.3.  In-Clinic Procedures Treatment Phase .......................................................................... 44 
10.3.1.  Study Drug Administration ............................................................................................... 44 
10.3.2.  Procedures on Dosing Days (Days 1, 8, 15, 22, & 29) during Period 1 ........................... 46 
10.3.3.  Procedures for In -Clinic Days during Period 1 ................................................................. 47 
10.4.  Procedures on TDS Removal Days (Days 8, 15, 22, 29 & 36) during Period 1 ........... 48 
10.4.1.  Study Drug Administration (Period 2 & 3) Treatment B  .................................................. 49 
10.4.2.  Procedures on In- Clinic Days Period 2 & 3 Treatment B & C  ......................................... 50 
10.4.3.  Procedures on TDS Removal Day Treatment B Periods 2 & 3 (Days 44, 51, 58, 65, 72, 
80, 87, 94, 101, 108): ......................................................................................................................... 50 
10.4.4.  Procedures for Drug Administration Treatment C (Period 2 & 3).................................... 51 
10.4.5.  End of Treatment (Day 109) ............................................................................................. 51 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 5 of 78  October 2 6, 2020 
 10.5.  Unscheduled Assessments and Early Termination Visits ............................................. 52 
10.5.1.  Unscheduled Assessments  ................................................................................................ 52 
10.5.2.  Early Termination (ET)  .................................................................................................... 52 
10.6.  Follow- Up Visit  ............................................................................................................ 53 
10.7.  End of Study (EOS) ...................................................................................................... 54 
11. CONCOMITANT MEDICATIONS AND RESTRICTIONS  .................................... 54 
11.1.  Concurrent Medication Restrictions ............................................................................. 54 
11.2.  Dietary Restrictions  ...................................................................................................... 55 
11.3.  General Restrictions  ...................................................................................................... 55 
12. INVESTIGATIONAL PRODUCT ................................................................................ 56 
12.1.  Active Pharmaceutical Ingredients  ............................................................................... 56 
12.2.  Pharmaceutical Treatments  ........................................................................................... 56 
12.3.  Supply of Study Drug ................................................................................................... 56 
12.4.  Packaging and Labeling ................................................................................................ 57 
12.5.  Materials Control .......................................................................................................... 57 
12.6.  Storage of Study Drug .................................................................................................. 57 
12.7.  Study Drug Accountability ........................................................................................... 57 
13. SAFETY ASSESSMENT  ............................................................................................... 58 
13.1.  Medical History  ............................................................................................................ 58 
13.2.  Physical Examination .................................................................................................... 58 
13.3.  Columbia- Suicide Severity Rating Scale (C -SSRS)  ..................................................... 58 
13.4.  Vital Signs  ..................................................................................................................... 58 
13.5.  12-Lead Electrocardiogram  .......................................................................................... 58 
13.6.  Clinical Laboratory Measurements ............................................................................... 59 
13.7.  COVID-19 Testing........................................................................................................ 60 
13.8.  Adverse Event Assessments ......................................................................................... 60 
14. PHARMACOKINETIC ASSESSMENTS .................................................................... 60 
14.1.  Pharmacokinetic Plasma Sample Collection  ................................................................ 60 
14.2.  Pharmacokinetic Sample Shipment  .............................................................................. 61 
14.3.  Bioanalytical Methodology ........................................................................................... 62 
14.4.  Subjects to Analyze....................................................................................................... 62 
15. ADHESION ASSESSMENTS AND PATCH PHOTOGRAPHY  .............................. 62 
15.1.  Patch Detachment  ......................................................................................................... 63 
16. IRRITATION ASSESSMENTS/SKIN TOLERABILITY  ......................................... 63 
16.1.  Tolerability Scales (Dermal Response and Other Effects)  ........................................... 63 
17. DISCONTINUATION AND REPLACEMENT OF SUBJECTS  .............................. 64 
17.1.  Withdrawal of Subjects from the Study ........................................................................ 64 
17.2.  Withdrawal of Subjects Post-Dose Study Drug ............................................................ 65 
17.3.  Replacement of Subjects  ............................................................................................... 65 
18. STATISTICAL METHODS  .......................................................................................... 65 
18.1.  Analysis Populations ..................................................................................................... 66 
18.2.  Determination of Sample Size  ...................................................................................... 66 
18.3.  Pharmacokinetic Analysis  ............................................................................................. 67 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 6 of 78  October 2 6, 2020 
 18.3.1.  Pharmacokinetic Parameters ............................................................................................. 67 
18.3.2.  Descriptive Statistics for Pharmacokinetics  ...................................................................... 67 
18.3.3.  Plasma Concentration -Time Plots  ..................................................................................... 67 
18.3.4.  Statistical PK Comparison between Treatments  ............................................................... 68 
18.3.5.  Time to Steady State Assessment  ..................................................................................... 68 
18.3.6.  Statistical Assessment of Relative Bioavailability ............................................................ 68 
18.4.  Adhesion Analysis ........................................................................................................ 69 
18.5.  Subject Disposition and Demographic/Baseline Characteristics  .................................. 69 
18.6.  Safety A nalysis ............................................................................................................. 70 
18.7.  Interim Analysis  ............................................................................................................ 70 
19. ADVERSE EXPERIENCE REPORTING AND DOCUMENTATION ................... 70 
19.1.  Adverse Events  ............................................................................................................. 70 
19.1.1.  Recording and Monitoring of Adverse Events ................................................................. 70 
19.1.2.  Definition  .......................................................................................................................... 70 
19.1.3.  AE Grading  ....................................................................................................................... 71 
19.1.4.  AE Relationship to Study Drug ........................................................................................ 71 
19.2.  Serious Adverse Events ................................................................................................ 72 
19.2.1.  Serious Adverse Event Reporting ..................................................................................... 72 
19.3.  Adverse Event Treatment and Follow-up ..................................................................... 74 
20. PREGNANCY  ................................................................................................................. 74 
21. PROTOCOL VIOLATIONS  ......................................................................................... 74 
22. DATA MANAGEMENT AND RECORD KEEPING ................................................. 75 
22.1.  Data Management  ......................................................................................................... 75 
22.2.  Record Keeping ............................................................................................................ 75 
22.3.  Access to Source Data/Documents  ............................................................................... 75 
23. QUALITY CONTROL AND QUALITY ASSURANCE  ............................................ 75 
24. ETHICS AND GOOD CLINICAL PRACTICE COMPLIANCE  ............................. 76 
25. PUBLICATION POLICY .............................................................................................. 76 
26. FINANCING AND INSURANCE  ................................................................................. 76 
26.1.  Finances  ........................................................................................................................ 76 
26.2.  Insurance Compensation ............................................................................................... 76 
27. COMPLETION OF STUDY  .......................................................................................... 76 
28. STUDY ADMINISTRATIVE INFORMATION ......................................................... 77 
28.1.  Protocol Amendments ................................................................................................... 77 
29. REFERENCES  ................................................................................................................ 78 
 
  
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 7 of 78  October 2 6, 2020 
 LIST OF ABBREVIATIONS  
AE Adverse Event 
ADL  Activity of Daily Living  
ALT  Alanine transaminase  
AST  Aspartate aminotransferase, Aspartate transaminase  
AUC  Area under the plasma concentration -time curve  
β-hCG  Beta human chorionic gonadotropin  
BLQ  Below the limit of quantification  
BMI  Body Mass Index  
CFR  Code of Federal Regulation s 
CI Confidence I nterval  
CKD- EPI Chronic Kidney Disease Epidemiology Collaboration estimated glomerular 
filtration rate (eGFR)  
Cmax Maximum observed plasma concentration  
Cmin Minimum observed plasma concentration  
Ctau Plasma concentration at the end of a dosing interval at steady state  
COVID -19 Coronavirus  Disease 2019  
CRF  Case Report Form  
CRO  Contract Research Organization  
CRU  Clinical Research Unit  
C-SSRS  Columbia -Suicide Severity Rating Scale  
CTCAE  Common Terminology Criteria for Adverse Events  
CV Coefficient of V ariation  
ECG  Electrocardiogram  
eCRF  Electronic Case Report Form 
EDC  Electronic Data Capture  
EOS  End of S tudy  
ET Early Termination  
FDA  Food and Drug Administration  
FLUCP  Percent peak -to-trough fluctuation  
GCP  Good Clinical Practice  
HIPAA  Health Insurance Portability and Accountability Act  
HIV Human Immunodeficiency V irus 
ICF Informed Consent F orm 
ICH International Conference on Harmonization  
IND Investigational New Drug  
IP Investigational Product  
IRB Institutional Review Board  
IUD Intrauterine device  
LSGM  Least squares geometric mean  
MedDRA  Medical Dictionary of Regulatory Activities  
OTC  Over the  Counter  
PD Pharmacodynamic  
PK Pharmacokinetic  
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 8 of 78  October 2 6, 2020 
 PT Prothrombin Time  
PTT Partial Thromboplastin Time  
Q1 25th Percentile (1st Quartile)  
Q3 75th Percentile (3rd Quartile)  
QTcF 
 Time between the start of the Q wave and the end of the T wave (QT interval) in  
the heart's electrical cycle, corrected for heart rate with Fridericias’s formula  
RLD  Reference Listed Drug  
SAE  Serious Adverse Event 
SAP Statistical Analysis Plan  
SOE  Schedule of Events  
SS Steady State  
TDS  Transdermal Delivery System  
TEAE  Treatment -Emergent Adverse E vent 
Tlag Lag time: time prior to the first measurable (non -zero) concentration  
Tmax Time to achieve the maximum observed plasma concentration  
ULN  Upper Limit of Normal  
  
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 9 of 78  October 2 6, 2020 
 PROTOCOL SYNOPSIS  
TITLE  A Phase 1, Open -Label, 3 -Period, Randomized, Crossover 
Pharmacokinetic Study to Evaluate the Steady- State 
Pharmacokinetics of 5 mg and 10 mg Corplex™ Donepezil 
Transdermal Delivery Systems Compared to 10 mg Oral 
Administration of Aricept® in Healthy Volunt eers 
SPONSOR  Corium, Inc.  
PROTOCOL NUMBER  CL-P-20003  
INVESTIGATIONAL 
PRODUCT  Corplex™ Donepezil Transdermal Delivery System (TDS) is 
a matrix type transdermal patch manufactured for a 7-day 
application.  
NAME OF ACTIVE 
INGREDIENT  Donepezil  
ROUTE  Oral/Transdermal  (TDS)  
NUMBER OF SITES  1 
STUDY DESIGN  This is a Phase 1, open -label, randomized, 3 -period, 3 -
treament, crossover pharmacokinetic study to evaluate the steady -state pharmacokinetics of 5  mg and 10 mg Corplex™ 
Donepezil TDS manufactured with the commercial process compared to 10 mg oral administration of Aricept
® in healthy 
volunteers. 
The study will consist of a Screening Period, a Treatment Phase with 3  treatment periods and a Follow- Up Visit, as 
follows: 
• Screening Period: Subjects will undergo a Screening Period up to 28 days prior to entering the Treatment Phase.  
• Treatment Phase: Eligible subjects will participate in 3 treatment periods each consisting of 36 days, without a washout between treatments.  
o Treatment A : 5 mg/day Donepezil 
Transdermal Delivery System (TDS) for 5 consecutive weeks (7 -day wear for each of 
the 5 patches). In Period 1, all enrolled subjects will receive Treatment A. The last (5
th) patch will be removed on the morning of 
Day 36 (168 hours after the last  patch 
application). No study drug will be administered on Day 36. 
During Period 1, t he 5 mg/day Donepezil TDS as the first 
treatment of the study allows subjects to get accustomed to the potential cholinergic effects (5  mg/day for 1 week is the 
recommended starting dose before titrating up, to 10 mg/day). 
In this study, the 5  mg/day Donepezil TDS is administered for 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 10 of 78  October 2 6, 2020 
 5 weeks to reach steady state in order to measure the steady 
state pharmacokinetics in Week 5  to be compared with those 
after oral Aricept®. 
 
During Treatment Periods 2 and 3, the subjects will be randomized to receive either sequences of Treatments B -C or 
Treatments C -B. Subjects will receive the following 
treatments according to the randomization schedule. 
o Treatment B : 10 mg/day Donepezil TDS 
applied weekly (within ±1 hour of application time on Day  1) for 5  consecutive weeks  
o Treatment C : 10 mg Aricept
® donepezil tablet 
administered QD for 5  weeks (within ±1 hour 
of dosing time on Day 1). 
Randomization to the 2 treatment sequences will be stratified by gender. For all oral doses and TDS applications, subjects will receive a light meal 30  minutes prior to dosing. Standard meals will 
be provided at appropriate times thereafter. Blood samples for pharmacokinetics and safety assessments will be collected during the Treatment Phase.  See Treatment Phase Schematic (Section  2). 
In each period wherein the treatment consists of a patch, the subjects will wear a total of 5 patches (1 per week) for a total of 35 days (5 weeks). The last (5
th) patch in the period will be 
removed after the morning blood draw on Day 36 ( 168-hour 
time point after the last patch in the period). No treatment will be administered on Day 36 of the period; additional post- wear 
PK blood samples will be collected on Day 36 after a ny patch 
treatment.  
 In each period (Period 2 or 3) wherein the treatment consists of oral Aricept
®, the subjects will receive an oral dose daily 
for a total of 35 days (5 weeks). The last oral dose in the 
period will be administered on the morning of Day 35. No treatment will be administered on Day  36 of the period; a PK 
blood sample will be collected in the morning of Day 36 at 24 hours after the last oral dose.  In Period 1, all subjects will wear patches (Treatment  A). In 
Periods 2 and 3, subjects will either wear patches (Treatment  B) or receive once-per- day oral Aricept
® 
(Treatment  C).  
o The treatment in Period  2 will start on the morning of 
Study Day  37 after the pre -dose blood draw for 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 11 of 78  October 2 6, 2020 
 Period  2 is collected. No treatment will be 
administered on Study Day  72. For the patch treatment 
in Period 2, the patch will be removed on Study 
Day 72 after the 168-hour blood sample collection. 
o The treatment in Period  3 will start on the morning of 
Study Day 73 after the pre-dose blood draw for Period  3 is collected. No treatment will be 
administered on Study Day 108. For the patch treatment in Period  3, the patch will be removed on 
Study Day 108 after the 168-hour blood sample collection.  
 
• Follow- Up Visit : 5 ±2 days after the day of the last 
oral drug administration or last TDS removal during the Treatment Phase, subjects will enter a Follow -Up 
Visit to evaluate safety parameters.  
There will be no washout phase between treatment periods (with the exception of  Day  36 within each period 
to collect post -treatment PK blood samples).  
PRIMARY OBJECTIVE  To evaluate the bioequivalence of steady -state donepezil 
plasma exposure following once- weekly treatments with 
10 mg/day Corplex™ Donepezil TDS compared to once- daily 
oral administration of 10 mg Aricept®.  
SECONDARY  
OBJECTIVES 
 • To evaluate the bioequivalence of steady -state 
donepezil plasma exposure (after dose- normalization) 
following once- weekly treatments with 5  mg/day 
Corplex™ Donepezil TDS compared to once- daily 
oral administration of 10 mg Aricept®. 
• To evaluate the adhesion to the skin during the wear period of each once-weekly 5 mg/day and 10 mg/day 
Corplex™ Donepezil TDS  application.  
SAFETY OBJECTIVE  To evaluate the safety  and tolerability  (including local skin 
tolerability, which consists of Dermal Response and Other 
Effects)  of once -weekly  Corplex™ Donepezil TDS.  
NUMBER OF SUBJECTS  An appropriate number of subjects will enter the Screening 
Period to enroll approximately 60 subjects to c omplete with 
48 subjects during the Treatment Phase. 
SUBJECT SELECTION  
CRITERIA Inclusion Criteria  
1. Healthy males and females.  
2. Subject must be a male or non -pregnant, non-
breastfeeding female.  
3. Subject must be between 18 and 55 years of age (inclusive) at Screening.  
4. Subject's Body Mass Index (BMI) must be between 18 
and 32  kg/m2 (inclusive) and subject must weigh 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 12 of 78  October 2 6, 2020 
 between 60 and 100  kg (inclusive) at Screening.  
5. Subject must be continuous non- smokers and agree 
not to smoke during confinement fr om the time of 
screening and throughout the study. 
6. Subject must have a Fitzpatrick skin type of I, II or III 
or have skin colorimeter scores equivalent to the allowed Fitzpatrick skin type.  
7. Female subjects must agree to use one of the following forms of birth control from screening until 14 days after the End -of-Study Visit, unless a different 
timeframe is listed below: 
a) Vasectomized partner (at least 6  months prior 
to Screening). 
b) Post- menopausal (at least 2  years prior to 
Screening).  
c) Surgically sterile (bilateral tubal ligation, hysterectomy, bilateral oophorectomy) at least 6 months prior to Screening. 
d) Non-surgical sterilization (e.g., Essure
® 
procedure) at least 3 months prior to Screening.  
e) Double barrier (diaphragm with spermicide; condoms with spermicide)  
f) Intrauterine device (IUD)  
g) Total abstinence (must agree to use a double barrier method if they become sexually active between Screening and 14  days after the End -
of-Study Visit).  
h) Implanted or intrauterine hormonal contraceptives in use for at le ast 3 consecutive 
months prior to Screening. 
i) Oral, patch, or injected contraceptives, or vaginal hormonal device (i.e., NuvaRing
®), in 
use for at least 3 consecutive months prior to Screening.  
8. Subject must be able to speak, read and understand English or Spanish.  
9. Subject must voluntarily consent to participate in this study and provide their written informed consent prior to start of any study- specific procedures.  
10. Subject is willing and able to remain in the study unit for the entire duration of each confinement period and return for the Follow- Up Visit.  
Exclusion Criteria  
1. History or presence of clinically significant 
cardiovascular, pulmonary, hepatic, renal, 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 13 of 78  October 2 6, 2020 
 hematologic, gastrointestinal, endocrine, 
immunologic, dermatologic, neurologic, oncologic, or 
psychiatric disease or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the subject or the validity of the study results. 
2. More specifically, subjects with a history of serious structural cardiac abn ormalities, cardiomyopathy, 
serious heart rhythm abnormalities, coronary artery disease, or other cardiac problems.  
3. More specifically, at the discretion of the Investigator, subjects with preexisting hypertension, heart failure, myocardial infarction, or ventricular arrhythmia/prior 
EEG abnormalities in absence of seizure.  
4. At the discretion of the Investigator, a clinically significant abnormal finding in the physical examination, vital signs, medical history (including a family history of sudden death/ventricular arrhythmia), electrocardiogram (ECG), or clinical laboratory results at Screening. 
5. After resting seated for at least 3  minutes, subjects 
should be excluded from the study with the following vital signs at Screening: 
a) a confirmed systolic blood pressure outside the range of 90-145 mmHg, or  
b) a confirmed diastolic blood pressure outside the range of 50-90 mmHg, or 
c) a confirmed resting heart rate outside the range of 40-100 beats per minute.  
6. Has an isolated a lanine aminotransferase (ALT) ≥1.5x 
the Upper L imit of Normal (ULN) or aspartate 
aminotransferase (AST) ≥1.5x the ULN at Screening; or both ALT and AST exceeding the ULN. 
7. Estimated creatinine clearance at screening <70 mL/min /1.73 m
2 using the CKD- EPI equation  
calculator ( Levey  2009).  
8. Prolonged corrected QT interval by Fridericia’s formula (QTcF) on screening electrocardiogram (ECG) (≥450  ms for both females and males).  
9. History of significant multiple and/or severe allergies (e.g., latex allergy, band aids, adhesive dressing, or medical  grade adhesive tape), or has had an 
anaphylactic reaction or significant intolerability to prescription or nonprescription drugs. 
10. Major surgery th at required general anesthesia within 
90 days prior to Screening. 
11. History or presence of hypersensitivity or 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 14 of 78  October 2 6, 2020 
 idiosyncratic reaction to the study drugs or related 
compounds (including piperidine derivatives and other 
cholinesterase inhibitors). 
12. At the discretion of the Investigator, on a significantly abnormal diet during the 4 weeks preceding Day  -1. 
13. History or presence of excessive hairy skin on application sites as deemed by the Investigator to potentially interfere with patch adhesion or drug absorption. 
14. History or presence of significant skin damage, diffuse skin diseases (e.g., diffuse psoriasis or eczema), s cars 
(flat scars, birth marks, moles, and stretch marks that do not affect skin surface are allowed), tattoos on the application sites or other skin disturbances (including sunburns, excessive tanning, and stretch marks) as deemed by the Investigator to potentially interfere with drug absorption or skin tolerability assessments 
15. Use of donepezil hydrochloride or related drugs within 60 days prior to the first study drug administration (oral administration or TDS application, as appropriate). 
16. Has donated ≥500 mL blood within 30 days or donated ≥500 mL plasma within 14  days prior to 
Day -1. 
17. Inadequate peripheral venous access that would interfere with obtaining blood samples. 
18. Has participated in another clinical trial (randomized subjects only) within 30 days prior to Day  -1. 
19. Has used any over the counter  (OTC) medication, 
including vitamins, herbal products, and dietary supplements within 14 days prior to Day -1. 
20. Has used any prescription medication, except hormonal contraceptive or hormonal replacement therapy , within 14 days prior to Day -1. 
21. Has a history of substance abuse or treatment (including alcohol) within 1 year prior to Screening. 
22. Is a female with a positive pregnancy test.  
23. Has a positive urine screen for drugs of abuse at Screening or Day  -1. 
24. Has a positive urine screen for alcohol on Screening or Day -1. 
25. Has a positive test for hepatitis B surface antigen, hepatitis C antibody, or human immunodeficiency virus (HIV) antibody at Screening or has been previously treated for hepatitis B, hepatitis C, or HIV 
infection.  
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 15 of 78  October 2 6, 2020 
 26. Has a n active  COVID -19 test at Screening  or Day -1. 
27. Has clinically significant gastrointestinal problems, 
including narrowing of the gastrointestinal tract, that may interfere with the gastrointestinal absorption of study drug. 
28. History of eating disorders within 3 months prior to Day -1. 
29. Has a history of unstable psychiatric illness requiring medications or hospitalization within 12  months prior 
to Day  -1, or exhibits marked anxiety, tension, or 
agitation.  
30. Specifically, diagnosis of comorbid bipolar disorder/comorbid depressive symptoms. 
31. Has a history of unexplained syncope. 
32. Subject has any history of attempted suicide or clinically significant suicidal ideation based on the C -
SSRS assessment, in the opinion of the Investigator, at Screening or Day -1. 
33. Has smoked or used tobacco products within 6 months prior to Day -1 or is currently using nicotine products; is unable to abstain from the use of any nicotine-containing products (including e- cigarettes, pipes, 
cigars, chewing tobacco, nicotine topical patches, nicotine gum, or nicotine lozenges ). 
34. Subject is a n employee or relative of any employee 
working for the CRO or Sponsor.  
TEST PRODUCT, DOSE, 
AND ROUTE OF ADMINISTRATION The study treatments are as follows:  
 Treatment A (Test): 5 mg/day Donepezil TDS manufactured 
with the commercial process applied weekly (within ±1  hour 
of application time on Day 1) for 5  consecutive weeks (7 -day 
wear each). All subjects will receive Treatment  A in Period 1. 
The patch will be removed on the morning of Day  36. 
 At the start of Period  2, subjects will be randomized to one of 
the following treatments in Period  2. Subjects will receive the 
alternate treatment in Period  3. Randomization to the 
2 treatment sequences will be stratified gender.  
 Treatment B (Test): 10 mg/day Corplex™ Donepezil TDS manufactured with the commercial process applied weekly (within ±1  hour of application time on Day 1) for 
5 consecutive weeks (7 -day wear each).  
 
Treatment C (Reference):  10 mg Aricept® donepezil (1 x 
10 mg/day tablet) administered QD for 35  consecutive days 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 16 of 78  October 2 6, 2020 
 (within ±1  hour of dosing time on Day  1). This is the 
Reference Listed Drug (RLD).  
 
See Treatment Phase Schematic (Section  2). 
In each period wherein the treatment consists of a patch, the subjects wi ll wear a total of 5  patches for a total of 35 days 
(5 weeks). The last (5
th) patch in the period will be removed 
after the morning blood draw on Day 36 (168-hour time point). No treatment will be administered on Day  36 of the 
period; additional post- wear PK blood samples will be 
collected on Day  36 after any patch treatment. 
 In each period wherein the treatment consists of oral Ari
cept®, the subjects will receive an oral dose daily for a 
total of 35 days (5 weeks). The last oral dose in the period will be administered on the morning of Day 35. No treatment will be administered on Day  36 of the period; a PK blood 
sample will be collected in the morning of Day 36 at 24 hours 
after the last oral dose.  
 In P
eriod 1, all subjects will wear patches (Treatment A). In 
Periods 2 and 3, subjects will either wear patches (Treatment B) or receive once-per- day oral Aricept
® (Treatment C).  
o The treatment in Period  2 will start on  the morning of 
Study Day 37 after the pre-dose blood draw for Period  2 is collected. No treatment will be 
administered on Study Day 72. For the patch treatment in Period 2, the patch will be removed on Study Day 72 after the 168-hour blood sample collection. 
o The treatment in Period  3 will start on the morning of 
Study Day 73 after the pre-dose blood draw for Period 3 is collected. No treatment will be administered on Study Day 108. For the patch treatment in Period 3, the patch will be removed on Study Day 108 after the 168-hour blood sample collection. 
 TDS Administration (Treatments  A a
 nd B) : 
• The pharmacy at the CRU will remove the TDS from refrigerated storage ( 2-8ºC) and place at room 
temperature storage (20-25ºC) on the day before 
application, no more than  24 hours prior to 
application. 
• The pharmacy at the CRU will prepare the Corplex™ Donepezil TDS for each subject (per the randomization and stratification scheme). Each TDS 
treatment will be applied to intact dry skin only on the 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 17 of 78  October 2 6, 2020 
 subject’s back weekly for 5  consecutive weeks. The 
most ideal naïve location on the back (back area that 
avoids the bra area and is slightly above the waistline is preferred) should be reserved for the last 5
th patch of 
the treatment sequence. If this is not possible Sponsor approval should be obtained and documented to apply 
the TDS to a previously used site. 
• It is recommended that the TDS is applied to the subject within 120 minutes of opening/removing from the packaging. 
• Subjects will be instructed to shower from 1 to 2 hours prior to each TDS application. No more than 1 shower a day is permitted and if showers are not taken, the following will be performed within 1 to 2 hours prior to each TDS application : the application  area will be 
washed with room temperature water using a wet washcloth. The application site will be patted dry and will be checked for irritancy.  
• The application area will be identified with a template 
overlay. The TDS will be placed at the designated 
application site and firm pressure will be applied 
immediately over the TDS for approximately 20 seconds using the palm of the hand on each TDS to ensure adhesion. A new TDS should not be applied to an area of skin where a TDS was just removed. The area selected should not be oily, damaged, or irritated and should not be exposed to sunlight. 
• No taping of the transdermal delivery systems will be 
allowed.  
• The exact clock time of TDS application and removal 
will be recorded for the start and end of TDS application. During each TDS treatment, the next TDS will be applied as soon as the previous TDS was removed. The change in TDSs should be performed within 15 minutes.  
 Oral Drug Administration (Treatment  C): 
Study drug will be given orally and be administered with approximately 240 mL of water. Subjects will be instructed 
not to crush, split, or chew the study drug tablets.  
EVALUATION CRITERIA  The evaluation criteria of the study are based on 
pharmacokinetic assessments , TDS adhesion assessments,  and 
safety evaluations.  
 
Pharmacokinetic Sampling (Days listed are  days within each 
period. See Treatment Phase Schematic, Section  2): 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 18 of 78  October 2 6, 2020 
 The blood PK samples will be collected at the nominal time 
points listed below ±5 minutes for the first 24 hours and 10 
minutes thereafter . 
Treatments A and B (patch applications):  
The fo llowing blood PK samples will be collected in 2 mL 
EDTA K2 lavender top tubes. 
• Week 1 (Days 1 to 7): Pre-TDS #1 application (Day  1), and at 2, 6, 12, 24, 48, 72, 96, 120, and 144 h 
after TDS #1 application. 
• Week 2 (Days 8 to 14): Pre-TDS #2 application (Day 8 at 168 h after TDS #1 application), and at 24, 
48, 72, 96, 120, and 144 h after TDS #2 application. 
• Week 3 (Day 15 to 21): Pre-TDS #3 application 
(Day  15 at 168 h after TDS #2 application). 
• Week 4 (Day 22 to 28): Pre-TDS #4 application 
(Day  22 at 168 h after TDS #3 application). 
The following blood PK samples will be collected in 4 mL EDTA K2 lavender top tubes. 
• Week 5 (Day 29 to 35): Pre-TDS #5 application (Day  29 at 168 h after TDS #4 application), and at 3, 
6, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, and 156 h after TDS #5 application 
• Week 6 (Day 36): Pre-TDS #5 removal (Day 36 at 168 h after TDS #5 application), and at 2, 6, 8, 10, and 12 h after TDS #5 removal  
 Treatment C (oral donepezil):  
The following blood PK samples will be collected in 2 mL EDTA K2 lavender top tubes. 
• Week 1, Day 1: Pre-Dose, and at 1, 2, 3, 4, 6, 8, 12 and 24 h after oral administration (before Day 2 oral administration)  
• Week 2: Day 8 Pre- Dose  
• Week 3: Day 15 Pre- Dose  
• Week 4: Day 22 Pre- Dose  
The following blood PK samples will be collected in 4 mL EDTA K2 lavender top tubes 
• Week 5: Day 29 Pre- Dose  
• Week 5: Day 35 Pre-Dose, and 1, 2, 3, 4, 6, 8, 12 and 24 h after oral administration (the 24 -h sample will be 
collected on Day  36) 
 Adhesion: 
Trained observers will determine the adhesion of each TDS as the percentage of the total surface area that is adhered to the 
skin. 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 19 of 78  October 2 6, 2020 
  
Safety:  
The Investigator will assess safety using the following 
parameters: physical examinations, vital sign assessments, 
clinical laboratory evaluations, C-SSRS evaluations, electrocardiograms,  and skin tolerability assessments (Dermal 
Response and Other Effects). Subjects will be monitored for any adverse events (AEs) from the time of first drug administration through the Follow- Up Visit.  
 
STUDY PARAMETERS  Pharmacokinetic  
Pharmacokinetic parameters at steady state (Week  5) 
calculated for plasma concentrations of donepezil and 6-O-
desmethyl donepezil (active metabolite)  will include AUC 0-
24,SS (daily AUC), AUC 0-168,SS, Cmax, Cmin, Cavg, Ctau, percent 
peak -to-trough fluctuation (FLUCP). After oral 
administration, AUC 0-24,SS will be calculated and multiplied 
by 7 to obtain AUC 0-168,SS . 
 Safety  
Safety will be assessed through 12-lead ECGs, vital sign measurements, clinical laboratory tests, suicidality monitoring (as per the C -SSRS), AEs, and physical examinations. Skin 
tolerability assessments will be performed for each TDS treatment prior to the TDS application and after removal of the TDS application.  Adhesion  
Adhesion assessments of each TDS will be collected  every 12 
hours during TDS wear as the percentage of the total surface area that is adhered to the skin , assessed in perso n by trained 
observers. With each consecutive measurement, observers 
will record the percentage based upon the actual measurement at each time point with the observer blinded to the previous recorded percentage finding . Tactile pressure to the TDS must 
not be applied during the adhesion determinations. 
 A grid 
overlay with  boxes will be used  to assist with estimating the 
% adhesion .  No taping of the TDS will be allowed. 
The time of full detachment of any TDS and its 0% adherence will be recorded , and the 0% adhesion will be assigned to all 
remaining adhesion time points  of the current wear period . 
At each adhesion assessment time point, a photograph will be taken as evidence of  the extent of TDS  adhesion to the skin 
(as support of the visual observation of the adhesion percentage but not to be used for automated or photometric 
analysis ). 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 20 of 78  October 2 6, 2020 
 Following removal of each TDS, the presence  or absen ce of 
remaining adhesive residue will be recorded.  
 
Skin Tolerability  
Skin Tolerability assessments will be performed prior to the TDS application and after removal of the TDS application during each period. If application site score is other than a 0 
prior to TDS application, another site will need to be used.  Residual Donepezil  
The used TDSs will be returned to Corium for residual drug analysis  (inclusive of any TDS that will be replaced during 
the study). 
 
STATISTICAL  
ANALYSES  Pharmacokinetics  
Plasma  concentrations and PK parameters of donepezil and 6-
O-desmethyl donepezil will be tabulated using summary statistics.  
To examine the donepezil PK at steady state (Week  5 of 5 x 
1-week wear) after 5 and 10 mg/day TDS application 
compared to oral Aricept
®, an analysis of variance (ANOVA) 
will be performed on the natural logarithms of AUC 0-168,SS  
and C max. Dose-normalization will be applied as appropriate. 
Differences between each Test and Reference in the PK parameters will be tested at the 5% level of significance.  
 Time to Steady State Assessment  
Assessment of time to achieve steady -state will be performed  
by a review of weekly donepezil trough levels (C tau) at time 
points immediately prior to dosing on Days 15, 22, 29, and 36 in each treatment period . The univariate analysis method 
described by Chow and Liu for examining when steady- state 
is attained will be implemented  using log-transformed trough 
plasma  concentrations. Modifications to the me thod for 
Treatment Period s 2 and  3 will be expla ined in the Statistical 
Analysis Plan ( SAP),  to possibly adjust for the attainment of 
a new steady state after switching to a new treatment with out 
a washout period after the previous treatment.  Relative Bi oavailab
 ility 
To examine the relative bioavailability at steady state of the 5 and 10 mg/day TDS (Tests) relative to oral donepezil (Reference), plasma donepezil exposure as characterized by AUC
0-168 at steady state will be assessed and compared 
utilizing bioequivalence criteria.  
Since the inten tion of the patch is to decrease the peak -to-
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 21 of 78  October 2 6, 2020 
 through fluctuations with lower C max after the patch 
application compared to daily oral Aricept dosing, rather than 
using the conventional bioequivalence criterion for C max, it is  
stipulated that  mean steady -state donepezil C max after patch 
administration  should remain  between the steady -state C max 
and C min after daily oral Aricept® administration.  
 Safety  
Adverse events will be coded using the current version of Medical Dictionary for Regulatory Activities
® (MedDRA) . 
The numbers of subjects with AEs, serious AEs (SAEs), and AEs leading to w ithdrawal from the study will be summarized 
by Preferred Term and System Organ Class for each treatment.  
Continuous safety data will be summarized by observed value and by change from baseline at each scheduled assessment.  
Concomitant medications will be c oded using the current 
version of World Health Organization drug dictionary and will be listed by subject. Columbia -Suicide Severity Rating 
Scale item responses will be listed and an overall summary of any suicidal ideation and behavior will be presented in tabular format.  
 Adhesion  
TDS adhesion score results  (percentage adhesion)  for each 
TDS strength will be summarized separately for Weeks 1 through 5 and across all wear periods (Weeks 1-5 combined) as follows: 
• Summary statistics (mean, SD, minimum, Q1, median, Q3, maximum) for the mean adhesion score, where the mean adhesion score for each patch is the average of the patch adhesion scores across the entire wear period.   
• Adhesion score distribution at each adhesion measurement time point post patch application (i.e., 12, 24, …, and 168 hours) 
• Average adhesion score at each adhesion 
measurement time point post patch application  
• Number (%) of patches that are completely detached  
during the 7- day wear period  
• Number (%) of patches with adhesion <50% at any 
adhesion measurement time point during the 7-day 
wear period  
• Summary of frequency of time a patch was first observed with adhesion <50% during the 7- day wear 
period  
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 22 of 78  October 2 6, 2020 
 • Number (%) of  patches with adhesion ≥75% at all 
adhesion assessment time points during the 7- day 
wear period  
  
To assess whether at least 80% of the TDS applied are at least 75% adhered throughout the 7-day wear period, a one-sided 95% confidence interval will be deter mined for the 
probability (p) that a randomly selected TDS maintains at least 75% adhesion throughout the entire wear period. If the 95% lower confidence limit for p is greater than 80%, acceptable TDS adhesion will be concluded. The method for the calculation of the 95% lower confidence limit and the justification of the method will be provided in the SAP.  To calculate the mean adhesion score and associated statistics , 
the lowest  adhesion score at each time point after the baseline 
time point (t
0) will be  carried  forward to subsequent time 
points until a lower  score is observed. 
 Patch Detachment:  
If a TDS partially or fully detaches from the skin, actions to reapply a detached area of the TDS, to apply pressure to the TDS, or to reinforce TDS adhesion with the skin (e.g., taping) must be avoided throughout the study. TDS detachment must not be inappropriately inhibited (e.g., by the constant pressure applied by a person or an object such as the back of a chair) . 
 If a TDS fully detaches fro m the skin, the TDS must not be 
reapplied and no fresh TDS will be applied for the remainder of the intended wear period. The time of full detachment of any TDS and its 0% adherence will be recorded, and the 0% adhesion will be assigned to all remaining ad hesion time 
points of the current wear period.  Skin Tolerability Assessments:  
Dermal response scores, other effects numerical scores, and the combined skin irritation score (calculated as the sum of the dermal response and other effects scores) will be summarized by post removal time point (0.5, 24, 48, 72 hours post removal).  The Dermal Response scale combined with the Other Effects scale is what defines the Local Skin Tolerability Assessment. Whole number scores will be used. When evaluating a dermal response, at least 25% or more of the patch area should demonstrate an observable response. When multiple observable dermal responses are present, each 
observable response shall represent at least 25% or more of 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 23 of 78  October 2 6, 2020 
 the patch area. It is recommended when determining the 
percentage of patch area with an observable response, record 
each dermal response and determine if each one response represents at least 25% or more of the patch area. Skin 
irritation will be followed until skin tolerability scores are ≤1. Separate summaries by treatment and by post removal assessment time point will be prov ided.   
If a TDS detaches, the t olerability scores will be collected for 
the site from which the TDS was removed.  Skin tolerability assessments will be performed prior to the TDS application and after removal of the TDS application during each period using the following scale:  Dermal Response  
Skin Appearance  Score  
No evidence of irritation  0 
Minimal erythema that is barely perceptible  1 
Definite erythema that is readily visible and 
minimal edema or minimal papular response  2 
Erythema and papules  3 
Definite edema  4 
Erythema, edema, and papules  5 
Vesicular eruption  6 
Strong reaction spreading beyond the 
application site  7 
 Other Effects  
 
 
Observation Score 
(Numerical  
Equivalent)  
Slightly glazed appearance  A (0)  
Markedly glazed appearance  B (1)  
Glazing with peeling and cracking  C (2)  
Glazing with fissures  F (3)  
Film of dried serous exudates covering 
all or part of the TDS site  G (3)  
Small petechial erosions and/or scabs  H (3)  
Source: FDA Draft Guidance: Assessing the Irritation and 
Sensitization Potential of Transdermal and Topical Delivery 
Systems for ANDAs. 2018  
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 24 of 78  October 2 6, 2020 
  
Residual Donepezil  
Results of the residual donepezil content from the used TDSs 
will be listed and an overall summary will be presented in a report.  
 
DURATION OF  SUBJECT  
PARTICIPATION AND DURATION OF STUDY Subjects will participate in the study for up to 144 days, 
including up to 28 days of screening, a Treatment Phase with 3 treatment periods of 36 days each, and a 5 ±2 day Follow-Up Visit. Eligible subjects will stay in the research clinic for 
109 days (108 overnight stays) during the Treatment Phase  
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 25 of 78  October 2 6, 2020 
 1. SCHEDULE OF  EVENTS  
 
STUDY PROCEDURES  
SCREENING  
Day -28 to Day -2 Treatment  Phase  
Period 1  
Day -1 through Day 36  Period 2: Day 37 through Day 72  
Period 3 Day 73 through Day 108  
Discharge Day 109  
Period 3  
Early Term12 
Follow -Up Day -1 
Day 1,8, 15, 
22, 29 
Day 2, 9, 16, 
23, 30  
Day 3, 10, 17, 
24, 31 
Day 4, 11, 18, 
25, 32  
Day 5, 12, 19, 
26, 33 
 
Day 6, 13, 20, 
27, 34 
Day 7, 14, 21, 
28, 35 
Day 8, 15, 22, 
& 29  
Day 36 
Day 37, 44, 
51, 58, 65, 73, 
80, 87, 94, 
0 
Day 38, 45, 
52, 59, 66, 
74 81  88  95  
 Day 39, 46, 
53, 60, 67, 75, 
82, 89, 96, 
  Day 40, 47, 
54, 61, 68, 76, 
83, 90, 97, 
104 
Day 41, 48, 
55, 62, 69, 77, 
84, 91, 98, 
 Day 42, 49, 
56, 63, 70, 78, 
85, 92, 99, 
 Day 43, 50, 
57, 64, 71, 79, 
86, 93, 100, 
 
Day 72 & 108  
Informed Consent  X                      
Inclusion/Exclusion Criteria  X X                     
Medical History  X X                     
Demographics  X                      
Skin Type Assessment  X                      
Physical Examination  X                   X X X 
Height & BMI  X                      
Weight  X                   X X  
12-Lead ECG1 X X                  X X  
Vital Signs2 X X X                X X X  
Hem, Serum Chem, Coag, 
UA3 X X         X        X  X  
COVID -19 Test54 X X                     
Pregnancy  Test (females 
only)  X X         X        X X X  
Urine Drug & Alcohol 
Screen  X X                     
Serology  X                      
C-SSRS5 X X         X        X  X  
Randomization             X           
Drug Administration6   X         X           
PK Sampling7                       
Adhesion Assessments8   X X X X X X X X X X X X X X X X X  X  
Skin Tolerability  
Assessments9                     X  
Skin Photography10   X X X X X X X X X X X X X X X X X  X  
TDS Removal11          X X        X    
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 26 of 78  October 2 6, 2020 
  
 
 
Abbreviations:  , Chem = Chemistry, Coag = Coagulation, ConMeds = Concomitant medication, C- SSRS = Columbia -Suicide 
Severity Rating Scale, ECG = Electrocardiogram, Hem = Hematology, , PK = Pharmacokinetic, TDS = Transdermal Delivery System, UA = Urin alysis.  
 
 1. ECG: A 12 -lead ECG will be obtained after the subject has been in the supine position for at least 3 minutes. Abnormal 
ECGs may be repeated for confirmation in which case only the repeated ECG will be recorded. The QT interval corrected for heart rate will be calculated with Fridericia’s formula (QTcF). Vital sign measurements will be obtained after the subject has been seated for at least 3 minutes. Vital signs will include sitting blood pressure (systolic and diastolic measurements), pulse rate (beats per minute), respiratory rate (breaths per minute), and oral temperature.  
2. Vital signs will be collected prior to the first dose/application of each treatment period and weekly thereafter.  Temperature checks may be permitted daily . 
3. Hematology, Serum Chemistry, Coagulation Panel, and Urinalysis: Laboratory safety tests will be obtained at the Screening visit, Day -1, Day 36, Day 72, Day 109, and at the Early Termination visit. 
4. COVID-19 Testing: Subjects must have an in active COVID -19 test at Scr eening and Day -1.  COVID -19 testing will occur 
weekly  while subjects are housed in the clinic. Additional test may be conducted a t the discretion of the Principle 
Investigator in consultation with the Medical Monitor.  
5. C-SSRS Columbia- Suicide Severity Rating Scale Assessments will be performed  at Screening, Day -1, Day 37, Day 72, 
Day 109, and the Early Termination  visit. 
6. Drug Administration: In Period 1, all subjects will wear patches (Treatment A). In Periods 2 and 3, subjec ts will either wear patches (Treatment 
B) or receive once-per- day oral Aricept (Treatment C). There is a treatment -free day on Day 36 of each period. 
In each period wherein the treatment consists of a patch, the subjects will wear a total of 5 patches for a total of 35 days (5 weeks). The last (5th) patch in the period will be removed after the morning blood draw on Day 36 (168 hour time point after the last patch in the period). No treatment will be administered on Day 36 of the period. In each period (Per iod 2 or 3) wherein the treatment consists of oral Aricept, the subjects will take an oral dose daily 
for a total of 35 days (5 weeks). The last oral dose in the period will be administered on the morning of Day 35. No treatment will be administered on Day  36 in each period. 
TDS Application:  Adverse Event Monitoring    X X X X X X X X X X X X X X X X X X X X 
ConMeds Monitoring  X X X X X X X X X X X X X X X X X X X X X X 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 27 of 78  October 2 6, 2020 
 • The pharmacy at the CRU will remove the TDS from refrigerated storage ( 2-8ºC) and place at room temperature 
storage (20 -25ºC) on the day before application to the skin, no more than 24 hours prior to application . 
• It is recommended that the TDS is applied to the subject within 120 minutes of opening/removing from the packaging. 
• Subjects will be instructed to shower from 1 to 2 hours prior to each TDS application. No more than 1 shower a day is 
permitted and if showers are not taken, the following will be performed within 1 to 2 hours prior to each TDS application, the application area will be washed with room temperature water using a wet washcloth. The application site will be patted dry and w ill be checked for irritancy.  
• The application area will be identified with a template overlay. The TDS will be placed at the designated application 
site and firm pressure will be applied immediately over the TDS for approximately 20 seconds using the palm of the 
hand on each TDS to ensure adhesion. A new TDS should not be applied to an area of skin where a TDS was just removed. The area selected should not be oily, damaged, or irritated and should not be exposed to sunlight. The exact clock time of TDS app lication and removal will be recorded for the start and end of TDS application. During 
each TDS treatment period, the next TDS will be applied as soon as the previous TDS was removed. The change in TDSs should be performed within 15 minutes. No taping of t he Transdermal Delivery Systems will be allowed.  
7. PK Sampling  (Days listed are within each period) The blood PK samples will be collected at the nominal time points listed 
below ±5 minutes for the first 24 hours  and 10 minutes thereafter: 
Treatments A and B  (patch applications): 
The following blood PK samples will be collected in 2 mL EDTA K2 lavender top tubes: 
• Week 1 (Days 1 to 7): Pre-TDS #1 application (Day 1), and at 2, 6, 12, 24, 48, 72, 96, 120, and 144 h after TDS #1 
application. 
• Week 2 (Days 8 to 14): Pre -TDS #2 application (Day 8 at 168 h after TDS #1 application, prior to removal), and at 24, 
48, 72, 96, 120, and 144 h after TDS #2 application. 
• Week 3 (Day 15 to 21): Pre-TDS #3 application (Day 15 at 168 h after TDS #2 application, prior to removal ). 
• Week 4 (Day 22 to 28): Pre-TDS #4 application (Day 22 at 168 h after TDS #3 application, prior to removal ). 
The following blood PK samples will be collected in 4 mL EDTA K2 lavender top tubes 
• Week 5 (Day 29 to 35): Pre-TDS #5 application (Day 29 at 168 h after TDS #4 application, prior to removal), and at 3, 
6, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, and 156 h after TDS #5 application 
• Week 6 (Day 36): Pre-TDS #5 removal (Day 36 at 168 h after TDS #5 application, prior to removal), and at 2, 6, 8, 10, and 12 h after TDS #5 removal 
Treatment C (oral dosing): The following blood PK samples will be collected in 2 mL EDTA K2 lavender top tubes: 
• Week 1, Day 1: Pre-Dose, and at 1, 2, 3, 4, 6, 8, 12 and 24 h after oral administration (before Day 2 oral administration)  
• Week 2: Day 8 Pre- Dose  
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 28 of 78  October 2 6, 2020 
 • Week 3: Day 15 Pre- Dose  
• Week 4: Day 22 Pre- Dose  
The following blood PK samples will be collected in 4 mL EDTA K2 lavender top tubes 
• Week 5: Day 29 Pre- Dose  
• Week 5: Day 35 Pre-Dose, and 1, 2, 3, 4, 6, 8, 12 and 24 h after oral administration (the 24 -h sample will be collected 
on Day 36).  
8. Adhesion Assessments: Treatment A and B  only - To be performed prior to TDS removal and at specified timepoints . 
Adhesion assessments will be performed at 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, and 168 hour following 
TDS application. The 168-hour assessment will be conducted prior to the next TDS application. Adhesion assessments will be performed in all periods within ± 1  hour of scheduled assessment.  
9. Irritation A ssessm
 ents: Treatment A and B  only - The site receiving the TDS should be assessed for skin irritation prior to 
TDS application (if the score is greater than zero another site must be selected)  for Period 1 . For TDS applied in during 
period 2 or 3, the site receiving the TDS should be assessed prior to TDS application (if the score is greater than zero another site must be selected) and the previous week’s TDS site should be assessed at 0.5, 24, 48 and 72 hours following TDS removal. If the score is greater  than 1 at 72 hours, assessments are to be performed at the following time points until 
the score returns to <1: 120 and 168 hours post-removal and then every 3 days. For TDS applied in Week 5, the site 
receiving the TDS should be assessed prior to TDS application (if the score is greater than zero another site must be selected) and the previous week’s TDS site should be assessed at 0.5, 24, 48 and 72 hours following TDS removal.  
10. Skin Photography: Treatment A & B  onl
 y - A photograph of the TDS will be taken in conjunction with the adhesion 
assessments.  Adhesion assessments will be performed at baseline and every 12 hours during TDS wear, and when the TDS is removed (including patch removal at or before Early Termination). 
11. TDS Removal: Treatment A and B  only – TDS r emoval will occur  on Day 8, Day 15, Day 22, Day 29, and Day 36 of 
Period 1 and Days 44, 51, 58, 65, 72, 80, 87, 94, 101, and 108 for Period 2 and 3.  Immediately after removal, used TDSs 
will be collected and returned to the Sponsor. After TDS  removal, the presence or absence of adhesive residue on the skin 
will be recorded . As soon as the TDS has been removed from the skin, the used TDS will be placed adhesive side down, on 
to a new release liner or folded in half and placed into a foil pouch. The sealed, labeled foil pouch and the corresponding original labeled patch pouch will then be inserted into a plastic bag and stored at approximately - 20°C ( -4°F) The used 
TDS will be shipped to the Sponsor, for residual drug determination. Additional instructions regarding application and removal of the TDS are provided in the Pharmacy Manual. 
12. Early Termination: Adhesion, tolerability and photos will be performed as needed if early termination occurs when the TDS is still being worn.  
 
 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 29 of 78  October 2 6, 2020 
  TREATMENT PHASE SCHEMATIC  
 
 
 
Treatment A:  5 mg/day TDS applied weekly, 7-day wear, removed in the morning of Period Day 36  
Treatment B:  10 mg/day TDS applied weekly, 7-day wear, removed in the morning of Period Day 36  
Treatment C:  10 mg oral Aricept® tablets, QD for 35 days (no dosing on Day 36 of the period) 
 TDS Application:  The first patch in each period with patch treatments (Treatment A or B) will be applied on Treatment Phase Days 
1, 37, and 73. For patches #2 to #4, at the end of each week of patch wear (168 h after application), the worn patch will be removed and a new patch will be applied. The 168-h post-dose PK blood samples will be collected before removal of the worn patch. The last (5
th) patch in each period with patch treatments (Treatment A or B) will be removed after 168 hours of the last patch 
application, after the 168-h PK blood sample collection. Oral Dosing:  In periods with oral Aricept (Treatment C), a single dose will be administered daily on Treatment Phase Days 37-71 
(Period 2) and 73-107 (period 3). Drug -Free Days:  There is no study drug administration (neither patch wear nor oral dosing) on Treatment Phase Days 36, 72, and 
108. 

Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 30 of 78  October 2 6, 2020 
  
2. BACKGROUND  
2.1. Alzheimer’s D isease (AD)  
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder of unknown etiology, 
characterized by progressive cognitive decline. Due to the role of cholinergic forebrain projections in memory and learning, several researchers proposed a cholinergic hypothesis to explain at least some of the features of AD. In the cholinergic hypothesis, cholinergic neurons emanating from the 
basal forebrain (nucleus of Meynert) are selectively lost. A corollary of this hypothesis is that 
augmentation of available cholinergic input to the forebrain could ameliorate AD symptoms. One method to augment cholinergic input would be to increase the levels of acetylcholine (ACh) in the synaptic cleft by inhibiting its degradation by the enzyme acetylcholinesterase (AChE ). 
 
2.2. Donepezil  
Donepezil HCl is one of 5 drugs approved for the treatment of AD. Aricept
® (donepezil HCl) is 
approved for the treatment of mild to severe AD, and is available as 5, 10, and 23 mg tablets. Donepezil is a reversible inhibitor of the enzyme AChE. D onepezil is postulated to exert its 
therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by AChE. While there is no evidence that donepezil alters the course of the underlying dementing process, 6 to 
12-month controlled studies have shown modest cognitive and/or behavioral benefits in patients 
with AD.   Corium is developing Corplex
TM Donepezil TDS, a matrix type transdermal patch that is 
designed for donepezil delivery over a 7-day wear period. A transdermal form of donepezil may benefit patients by potentially reducing gastrointestinal side effects (by bypassing the GI tract) and by improving treatment efficacy (through consistent, constant delivery, preventing missed doses and patient non- compliance). 
 
3. OVERVIEW OF CLINICAL STUDIES   
The clinical development program for Corplex
TM Donepezil TDS consists currently of ten Phase 
1 studies in healthy volunteers as shown in Table 1.  
 
   
 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 31 of 78  October 2 6, 2020 
 Table 1  List of Clinical Studies with CorplexTM Donepezil TDS  
Study 
Category  Study 
Number  Study Title  Brief Objectives  
Early 
Development  P-15007  A Phase 1 Crossover Study to Evaluate the Pharmacokinetics, 
Pharmacodynamics and Safety of Two Formulations of a 7 -Day 
Application of Donepezil Transdermal Delivery System 
Compared to Oral Administration of Aricept in Healthy 
Volunteers  Assess initial TDS 
formulation performance  
P-15081  A Phase 1 Parallel Study to Evaluate the Pharmacokinetics (PK), 
Pharmacodynamics (PD) and Safety of Formulations of a 7- Day 
Application Donepezil Transdermal Delivery System (TDS) in 
Healthy Female Volunteers  Formulation Selection  
P-16007  A Phase 1 Study to Evaluate the Adhesion, Pharmacokinetics 
(PK) and Safety of a Seven -Day Application of Donepezil 
Transdermal Delivery System (TDS) in Healthy Volunteers  Adhesion Optimization  
Key – Pivotal  P-15086  A Phase 1, Randomized, Open -Label, 3 -Way Crossover, Pilot, 
Pharmacokinetic Study to Evaluate the Steady State 
Pharmacokinetics of a Once- Weekly Application of Corplex™ 
Donepezil Transdermal Delivery System Compared to Daily 
Oral Administration of Aricept® in Healthy Adult Subjects  Steady state 
Bioequivalence  
Key – 
Supportive  P-16011  A Randomized Double -Blind Study to Assess the Skin 
Irritation and Sensitization Potential of Once -Weekly 
Corplex™ Donepezil Transdermal Delivery System  Skin Irritation/ 
Sensitization  
P-16012  A Phase 1, Crossover Study to Evaluate the Pharmacokinetics 
of CorplexTM Donepezil 10 mg Transdermal Delivery System 
Applied to Different Body Locations  Relative Bioavailability 
- Application Site (back, 
thigh, buttock)  
P-16039  A Phase 1, 2 -Way Crossover Study to Evaluate the Effect of 
Heat Application on the Pharmacokinetics of Corplex™ Donepezil 5 mg Transdermal Delivery System (TDS) in Healthy 
Volunteers  Relative Bioavailability 
– Applied Heat  
Supportive  P-16010  A Study to Assess the Steady State Bioequivalence of Once -
Weekly Corplex™ Donepezil 10 mg Transdermal Delivery System Compared to Daily Oral Administration of Aricept® Safety/Tolerability and 
Adhesion  
P-15086 
Sub-
Study1 A Phase 1, Randomized, Open -Label, 2 -Way Crossover Study, 
to Compare the Relative Bioavailability of Two Corplex Donepezil Transdermal Delivery Systems’ Manufactured Using 
Active Pharmaceutical Ingredient from 2 Different Suppliers  Relative Bioavailability  
- API Suppliers  
P-19005  A Phase 1, Randomized, Blinded, 2 -Way Crossover Study to 
Assess the Relative Bioavailability of Corplex™ Donepezil 
Transdermal Delivery Systems With and Without Crystals  Relative Bioavailability 
– With vs Without 
Crystals  
API =  Active Pharmaceutical Ingredient  
1 The P -15086 Sub -Study was conducted as an amendment to Protocol No. P -15086.  
 
Across all Phase 1 studies conducted to date with Donepezil and CorplexTM Donepezil TDS (any 
formulation), no safety concerns specific to Donepezil or CorplexTM Donepezil TDS have been 
identified. Most systemic adverse effects have been consistent with those described in the package insert for Aricept. Application site -related A Es accounted for the greatest differences in AEs 
reported with Corplex
TM Donepezil TDS versus those reported with Aricept (due to the nature of 
transdermal delivery system). The most frequently reported AEs considered related to the TDS were nausea, headac he, application site pruritus, application site erythema, and nightmare. Headache and 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 32 of 78  October 2 6, 2020 
 nausea were also observed following treatment with oral Aricept. Application site -related AEs were 
largely mild in severity and skin irritation assessments demonstrated that most application site 
irritation was scored as not detected or mild and decreased over wear duration. In studies of 
CorplexTM Donepezil TDS there were not apparent differences in the incidence and quality of AEs 
reported for subjects using regimens that titrated doses (5 mg/day initial dose) upward to the 10 
mg/day target dose and those that did not titrate (initial dose was 10 mg/day). Both regimens yielded comparable adverse event profiles.  
With regard to the pharmacokinetics of donepezil after Corple x
TM Donepezil TDS application, of 
note is Study P -15086 wherein bioequivalence was demonstrated between the registration batch of 
the CorplexTM Donepezil TDS (TDS A) and oral Aricept®. The mean steady state donepezil plasma 
concentration -time profiles afte r weekly donepezil TDS application (TDS A, 10 mg/day) and daily 
oral 10 mg/day Aricept are shown in Figure 1. In accordance with the long donepezil half -life of 
approximately 70 hours, steady state was reached by Day 29, at the beginning of Week 5 during which the steady state exposure was evaluated. In line with the intension of the TDS application to 
also decrease the peak -to-through fluctuations of plasma donepezil concentrations, a lower 
donepezil C
max after the TDS application was observed compared to daily oral Aricept dosing. The 
mean steady -state donepezil concentrations after TDS application fell between the steady- state C max 
and C min after daily oral Aricept administration at most time points.  
Corium has made changes to the intended commercial manufacturing process including changes to 
increase the bond strength between the active layer and the overlay portion of the patch. Since these 
and other changes may be considered major differences compared to the process used for the clinical batch used in S tudy P -15086, the purpose of the current study is to demonstrate bioequivalence at 
steady state between the highest strength (10 mg/day) TDS manufactured with the new manufacturing process and oral 10 mg/day Aricept
®. 
In clinical practice, some patients ar e taking 5 mg/day Aricept®, and donepezil -naïve patients 
typically receive 5 mg/day oral Aricept doses as a lead -in before safely escalating to a 10 mg/day 
dose. Therefore, Corium had also developed a 5 mg/day CorplexTM Donepezil TDS by using half 
the patc h size as in the 10 mg/day TDS. The current study will therefore also evaluate the 
bioequivalence of steady -state donepezil plasma exposure (after dose- normalization) following 
once- weekly treatments with 5 mg/day CorplexTM Donepezil TDS compared to once-daily oral 
administration of 10 mg Aricept®. Bioequivalence is expected since it has been demonstrated that 
the pharmacokinetics of donepezil are linear over a dose range of 1- 10 mg given once daily 
(Aricept® label, Eisai Inc, 2012 ). In addition, the 5 -mg/d ay TDS application in the first study period 
for all subjects of the current study will allow safe escalation to 10 mg/day in the next study period.  
Refer to the Investigator’s Brochure (IB) for detailed background information on CorplexTM 
Donepezil TDS, a nd to the prescribing information for oral Aricept® (Aricept® label, Eisai Inc, 
2018). 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 33 of 78  October 2 6, 2020 
 4. STUDY RATIONALE  
The study is being conducted to evaluate the steady- state pharmacokinetics of 5 mg /day and 10 
mg/day Corplex™ Donepezil TDS manufactured with the commercial process compared to 10 mg 
oral administration of Aricept® in healthy volunteers. 
5. STUDY OBJECTIVES  
5.1. Primary Objective  
To evaluate the bioequivalence of steady -state donepezil plasma exposure following once -weekly 
treatments with 10 mg/day Corplex™ Donepezil TDS compared to once -daily oral administration 
of 10 mg Aricept®. 
5.2. Secondary Objectives 
• To evaluate the bioequivalence of steady -state donepezil plasma exposure (after dose -
normalization) following once -weekly treatments with 5 mg/day Corplex™ Donepezil TDS 
compared to once- daily oral administration of 10 mg Aricept ®.  
• To evaluate the adhesion to the skin during the wear period of each once -weekly 5 mg/day 
and 10 mg/ day Corplex™ Donepezil TDS application  
5.3. Safety Objective  
To evaluate the safety  and tolerability, including local  skin tolerability (Dermal Response and Other 
Effects)  of once -weekly Corplex™ Donepezil TDS. 
6. INVESTIGATIONAL PLAN 
6.1. Study Design  
This is a Phase 1, open- label, randomized, 3 -period, 3 -treament, crossover pharmacokinetic study 
to evaluate the steady- state pharmacokinetics of 5 mg /day and 10 mg /day Corplex™ Donepezil 
TDS manufactured with the commercial process compared to 10 mg oral administration of Aricept® 
in healthy volunteers .  
The study will consist of a Screening Period, a Treatment Phase with 3 treatment periods and a 
Follow- Up Visit, as follows : 
• Screening Period:  Subjects will undergo a Screening Period up to 28 days prior to 
entering the Treatment Phase . 
 
• Treatment Phase:  Eligible subjects will participate in 3 treatment periods each consisting 
of 36 days, without a washout between treatments.  
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 34 of 78  October 2 6, 2020 
 o Treatment A : 5 mg/day Donepezil Transdermal Delivery System (TDS) for 5 
consecutive weeks (7 -day wear for each of the 5 patches). In Period 1, all enrolled 
subjects will receive Treatment A. The last (5th) patch will be removed on the 
morning of Day 36 (168 hours after the last patch application). No study drug will 
be administered on Day 36. The 5 mg/day Donepezil TDS as the first treatment of the study allows  subjects to get accustomed to the potential cholinergic effects (5 
mg/day for 1 week is the recommended starting dose before titrating up, to 10 
mg/day). In this study, the 5 mg/day Donepezil TDS is administered for 5 weeks to 
reach steady state in order to measure the steady state pharmacokinetics in Week 5 to be compared with those after oral Aricept
®. 
During Treatment Periods 2 and 3, the subjects will be randomized to receive either sequences of 
Treatments B -C or Treatments C -B. Subjects will receive t he following treatments according to the 
randomization schedule.  
o Treatment B:  10 mg/day Donepezil TDS applied weekly (within ±1 hour of 
application time on Day 1) for 5 consecutive weeks  
 
o Treatment C:  10 mg Aricept® donepezil tablet administered QD for 5 weeks 
(within ±1 hour of dosing time on Day 1).  
Randomization to the 2 treat ment sequences will be stratified by the subject’s gender.   For all oral 
doses and TDS applications, subjects will receive a light meal 30 minutes prior to dosing. Standard 
meals will be provided at appropriate times thereafter. Blood samples for pharmacok inetics and 
safety assessments will be collected during the Treatment Phase. 
In each period wherein the treatment consists  of a patch, the subjects will wear a total of 5 patches 
for a total of 35 days (5 weeks). The last (5th) patch in the period will be removed after the morning 
blood draw on Day 36 (168 -hour time point after the last patch in the period). No treatment will be 
administered on Day 36 of the period; additional post- wear PK blood samples will be collected on 
Day 36 after any patch treatment.   Because of the lag time of donepezil plasma concentrations after 
TDS application, the C
max and T max values at steady state. in some subjects, may be observed after 
removal of the TDS (past 168 hours after TDS application). This is the reason why an addit ional 
day (Day 36 in each treatment period) was added to the PK sampling schedule, after TDS removal at the end of the TDS dosing interval (168 hours). 
In each period (Period 2 or 3) wherein the treatment consists  of oral Aricept
®, the subjects will an 
oral dose daily for a total of 35 days (5 weeks). The last oral dose in the period will be administered 
on the morning of Day 35. No treatment will be administered on Day 36 of the period; a PK blood 
sample will be collected in the morning of Day 36 at 24 hours after the last oral dose.  
In Period 1, all subjects will wear patches (Treatment A). In Periods 2 and 3, subjects will either 
wear patches  (Treatment B) or receive once- per-day oral Aricept® (Treatment C).  
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 35 of 78  October 2 6, 2020 
  
o The treatment in Period 2 will start on the morning of Study Day 37 after the pre-dose blood draw for Period 2 is collected. No treatment will be administered on Study Day 72. For the patch treatment in Period 2, the patch will be removed on Study Day 72 after the 168-hour blood sample collection.  
o The treatment in Period 3 will start on the morning of Study Day 73 after the pre-dose blood draw for Period 3 is collected. No treatment will be administered on Study Day 108. For the patch treatment in Period 3, the patch will be removed on Study Day 108 after the 168 -hour blood sample collection. 
 
• Follow -Up Visit:  5 ±2 days after the day of the last oral drug administration or last TDS 
removal during the Treatment Phase, subjects will enter a Follow -Up Visit to evaluate safety 
parameters.  
There will be no washout phase between treatment periods (with the exception of Day 36 within 
each period to collect post -treatment PK blood samples).  
6.2. Study Duration  
Subjects will participate in the study for up to 144 days, including up to 28 days of screening, a 
Treat ment Phase with 3 treatment periods of 36 days each, and a 5 ±2 day Follow -Up Visit. Eligible 
subjects will stay in the research clinic for 109 days (108 overnight stays) during the Treatment 
Phase 
7. SUBJECT SELECTION  
7.1. Number of Subjects  
An appropriate number  of subjects will enter the Screening Period to enroll approximately 60 
subjects to complete with 4 8 subjects during the Treatment Phase.  
7.2. Study Population  
Healthy male and female subjects who meet  the inclusion/exclusion criteria listed below.  
7.2.1.  Inclusion C riteria  
A subject will be eligible for inclusion in the study if all the following criteria apply: 
1. Healthy males and females.  
2. Subject must be a male or non -pregnant, non -breastfeeding female.  
3. Subject must be between 18 and 55 years of age (inclusive) at Sc reening. 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 36 of 78  October 2 6, 2020 
 4. Subject's Body Mass Index (BMI) must be between 18 and 32 kg/m2 (inclusive) and subject 
must weigh between 60 and 100 kg (inclusive) at Screening. 
5. Subject must be continuous non -smokers and agree not to smoke during confinement and 
from the time of screening and throughout the study.  
6. Subject must have a Fitzpatrick skin type of I, II or III or have skin colorimeter scores equivalent to the allowed Fitzpatrick skin type.  
7. Female subjects must agree to use one of the following forms of birth control from screening 
until 14 days after the End-of- Study Visit, unless a different timeframe is listed below:  
a) Vasectomized partner (at least 6 months prior to Scr eening). 
b) Post-menopausal (at least 2 years prior to Screening). 
c) Surgically sterile (bilateral tubal ligation, hysterectomy, bilateral oophorectomy) at least 
6 months prior to Screening.  
d) Non-surgical sterilization (e.g., Essure
® procedure) at least 3 months  prior to Screening.  
e) Double barrier (diaphragm with spermicide; condoms with spermicide) 
f) Intrauterine device (IUD) 
g) Total abstinence (must agree to use a double barrier method if they become sexually active between Screening and 14 days after the End-of- Study Visit).  
h) Implanted or intrauterine hormonal contraceptives in use for at least 3 consecutive months prior to Screening.  
i) Oral, patch, or injected contraceptives, or vaginal hormonal device (i.e., NuvaRing
®), in 
use for at least 3 consecutive months prior to Screening.  
8. Subject must be able to speak, read and understand English or Spanish.  
9. Subject must voluntarily consent to participate in this study and provide their written 
informed consent prior to start of any study-specific procedures 
10. Subject is willin g and able to remain in the study unit for the entire duration of each 
confinement period and return for the Follow- Up Visit . 
 
7.2.2.  Exclusion Criteria  
A subject who meets any of the following exclusion criteria will not be enrolled into the study: 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 37 of 78  October 2 6, 2020 
 1. History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, 
hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease or any other condition that, in the opinion of the 
Investigator, would jeopardize the safety of the subject or the validity of the study results.  
2. More specifically, subjects with a history of serious structural cardiac abnormalities, 
cardiomyopathy, serious heart rhythm abnormalities, coronary artery diseas e, or other 
cardiac problems.  
3. More specifically, at the discretion of the Investigator, subjects with preexisting hypertension, heart failure, myocardial infarction, or ventricular arrhythmia/prior EEG abnormalities in absence of seizure. 
4. At the discretio n of the Investigator, a clinically significant abnormal finding in the physical 
examination, vital signs, medical history (including a family history of sudden death/ventricular arrhythmia), electrocardiogram (ECG), or clinical laboratory results at Screening. 
5. After resting seated for at least 3  minutes, subjects should be excluded from the study with 
the following vital signs at Screening:  
a) a confirmed systolic blood pressure outside the range of 90- 145 mmHg, or  
b) a confirmed diastolic blood pressure outside the range of 50-90 mmHg, or  
c) a confirmed resting heart rate outside the range of 40- 100 beats per minute. 
6. Has an isolated alanine aminotransferase (ALT) ≥1.5 x the Upper Limit of Normal (ULN) 
or aspartate aminotransferase (AST) ≥1.5 x the ULN at Screening; or both ALT and AST 
exceeding the ULN . 
7. Estimated creatinine clearance at screening <70 mL/min /1.73 m
2 using  the CKD -EPI 
equation calculator (Levey  2009).  
8. Prolonged corrected QT interval by Fridericia’s formula (QTcF) on screening 
electrocardiogram (E CG) (≥450  ms for both females and males).  
9. History of significant multiple and/or severe allergies (e.g., latex allergy, band aids, adhesive 
dressing, or medical grade adhesive tape), or has had an anaphylactic reaction or significant intolerability to pres cription or nonprescription drugs.  
10. Major surgery that  required general anesthesia within 90 days prior to Screening. 
11. History or presence of hypersensitivity or idiosyncratic reaction to the study drugs or related compounds (including piperidine derivatives and other cholinesterase inhibitors). 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 38 of 78  October 2 6, 2020 
 12. At the discretion of the Investigator, on a significantly abnormal diet during the 4 weeks 
preceding Day  -1. 
13. History or presence of excessive hairy skin on application sites as deemed by the 
Investigator to potentially interfere with patch adhesion or drug absorption. 
14. History or presence of significant skin damage, diffuse skin diseases (e.g., diffuse psoriasis 
or eczema), scars (flat scars, birth marks, moles, and stretch marks that do not affect skin surfa ce are allowed), tattoos on the application sites or other skin disturbances (including 
sunburns, excessive tanning, and stretch marks) as deemed by the Investigator to potentially interfere with drug absorption or skin tolerability assessments  
15. Use of donepezil hydrochloride or related drugs within 60 days prior to the first study drug administration (oral administration or TDS application, as appropriate). 
16. Has donated ≥500 mL blood within 30  days or donated ≥500 mL plasma within 14  days 
prior to Day  -1. 
17. Inadequate peripheral venous access that would interfere with obtaining blood samples.  
18. Has participated in another clinical trial (randomized subjects only) within 30  days prior to 
Day -1. 
19. Has used any over the counter (OTC) medication, including vitamins, herbal products, and dietary supplements within 14  days prior to Day -1. 
20. Has used any prescription medication, except hormonal contraceptive or hormonal 
replacement therapy, within 14  days prior to Day -1. 
21. Has a history of substance abuse or treatment (incl uding alcohol) within 1 year prior to 
Screening.  
22. Is a female with a positive pregnancy test.  
23. Has a positive urine screen for drugs of abuse at Screening or Day -1. 
24. Has a positive urine screen for alcohol on Screening or Day - 1. 
25. Has a positive test for hepa titis B surface antigen, hepatitis C antibody, or human 
immunodeficiency virus (HIV) antibody at Screening or has been previously treated for 
hepatitis B, hepatitis C, or HIV infection.  
26. Has an active  COVID- 19 test at Screening or Day -1.  
27. Has clinically significant gastrointestinal problems, including narrowing of the 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 39 of 78  October 2 6, 2020 
 gastrointestinal tract, that may interfere with the gastrointestinal absorption of study drug.  
28. History of eating disorders within 3 months prior to Day - 1. 
29. Has a history of unstable psychiatric illness requiring medications or hospitalization within 
12 months prior to Day -1, or exhibits marked anxiety, tension, or agitation.  
30. Specifically, diagnosis of comorbid bipolar disorder/comorbid depressive symptoms. 
31. Has a history of unexplained syncope. 
32. Subject has any history of attempted suicide or clinically significant suicidal ideation based on the C -SSRS assessment, in the opinion of the Investigator, at Screening or Day -1. 
33. Has smoked or us ed tobacco products within 6 months prior to Day -1 or is currently using 
nicotine products; is unable to abstain from the use of any nicotine -containing products 
(including e -cigarettes, pipes, cigars, chewing tobacco, nicotine topical patches, nicotine 
gum, or nicotine lozenges ). 
34. Subject is a n employee or relative of any employee working for the CRO or  the Sponsor . 
8. STUDY TREATMENTS  
8.1. Study Drug Treatments  
On Day - 1, eligible subjects will be checked into the research clinic to enter the Treatment Phase .  
The study treatments are as follows:  
Treatment A (Test):  5 mg/day Donepezil TDS manufactured with the commercial process applied 
weekly (within ±1 hour of application time on Day 1) for 5 consecutive weeks (7- day wear each). 
All subjects will receive Treatment A in Period 1. The patch will be removed on the morning of 
Day 36. 
At the start of Period 2, subjects will be randomized to one of the following treat ments in Period 2. 
Subjects will receive the alternate treatment in Period 3. Randomization to  the 2 treatment 
sequences will be stratified by gender.  
Treatment B (Test):  10 mg/day Corplex™ Donepezil TDS manufactured with the commercial 
process applied weekly (within ±1 hour of application time on Day 1) for 5 consecutive weeks (7-
day wear each).  
Treatment C (Reference):  10 mg Aricept
® donepezil (1 x 10 mg/day tablet) administered QD for 
35 consecutive days (within ±1 hour of dosing time on Day 1). This is the Reference Listed Drug 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 40 of 78  October 2 6, 2020 
 (RLD). See Section 2 for a treatment phase schematic.  
TDS Application:  The first patch in each period with patch treatments (Treatment A or B) will be 
applied on Treatment Phase Days 1, 37, and 73. For patches #2 to #4, at the end of each week of 
patch wear (168 h after application), the worn patch will be removed and a new patch will be 
applied. The 168- h post -dose PK blood samples will be collected before removal of the worn patch.  
The last (5th) patch in each period with patch tr eatments (Treatment A or B) will be removed after 
168 hours of the last patch application, after the 168- h PK blood sample collection.  
Oral Dosing:  In periods with oral Aricept (Treatment C), a single dose will be administered daily 
on Treatment Phase Days 37 -71 (Period 2) and 73 -107 (Period 3). 
Drug -Free Days:  There is no study drug administration (neither patch wear nor oral dosing) on 
Treatment Ph ase Days 36, 72, and 108. 
In each period wherein the treatment consists  of a patch, the subjects will wear a total of 5 patches 
for a total of 35 days (5 weeks). The last (5th) patch in the period will be removed after the morning blood draw on Day 36 ( 168-hour time point). No treatment will be administered on Day 36 of the 
period; additional post -wear PK blood samples will be collected on Day 36 after any patch 
treatment.  
In Period 1, all subjects will wear patches (Treatment A). In Periods 2 and 3, subjects will either wear patches (Treatment B) or receive once- per-day oral Aricept
® (Treatment C).  
The treatment in Period 2 will start on the morning of Study Day 37 after the pre-dose blood draw 
for Period 2 is collected. No treatment will be administ ered on Study Day 72. For the patch 
treatment in Period 2, the patch will be removed on Study Day 72 after the 168- hour blood sample 
collection.  
The treatment in Period 3 will start on the morning of Study Day 73 after the pre-dose blood draw 
for Period 3 is collected. No treatment will be administered on Study Day 108. For the patch 
treatment in Period 3, the patch will be removed on Study Day 108 after the 168- hour blood sample 
collection.  
TDS Administration (Treatments A and B): 
The pharmacy at the CRU will remove the TDS from refrigerated storage ( 2-8ºC) and place at room 
temperature  storage (20-25ºC ) on the day before application,  no more than 24  hou rs prior to 
application. The pharmacy at the CRU will prepare the Corplex™ Donepezil TDS for each subject 
(per the randomization and stratification scheme). Each TDS treatment will be applied to intact dry skin only on the subject’s back weekly for 5 consecutive weeks. The most ideal naïve location on 
the back (back area that avoids the bra area and is slight ly above the waistline is preferred) should 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 41 of 78  October 2 6, 2020 
 be reserved for the last TDS application  of each period . If this is not possible Sponsor approval 
should be obtained and documented to apply the TDS to a previously used site. 
• It is recommended that the TDS is ap plied to the subject within 120 minutes of 
opening/removing from the packaging. 
• Subjects will be instructed to shower from 1 to 2 hours prior to each TDS application. No 
more than 1 shower a day is permitted and if showers are not taken, the following will  be 
performed within 1 to 2 hours prior to each TDS application, the application  area will be 
washed with room temperature water using a wet washcloth. The application site will be patted dry and will be checked for irritancy.  
• The application area will be identified with a template overlay. The TDS will be placed at 
the designated application site and firm pressure will be applied immediately over the TDS 
for approximately 20 seconds using the palm of the hand on each TDS to ensure adhesion. A new T DS should not be applied to an area of skin where a TDS was just removed. The 
area selected should not be oily, damaged, or irritated and should not be exposed to sunlight.  
• No taping of the transdermal delivery systems will be allowed. 
• The exact clock time  of TDS application and removal will be recorded for the start and end 
of TDS application. During each TDS treatment, the next TDS will be applied as soon as the previous TDS was removed. The change in TDSs should be performed within 15 minutes.  
Oral Drug Administration (Treatment C):  
Study drug will be given orally and be administered with approximately 240 mL of water. Subjects will be instructed not to crush, split, or chew the study drug tablets . 
8.2. Treatment Assignment  
At the start of Period 2, subjects will be randomized to one of the following treatments in Period 2. Subjects will receive the alternate treatment in Period 3. Randomization to the 2 treatment sequences will be stratified by gender  using a computer -generated randomization scheme.  Study 
drug will be assigned  to each subject on each dosing day based on the randomization scheme.  
8.3. Blinding  
This is an open -label pharmacokinetic study ; therefore, s tudy treatments will not be blinded. 
8.4. Compliance  
Each dose of study drug will be administered in the research clinic by a pharmacy staff member or 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 42 of 78  October 2 6, 2020 
 Investigator- delegated employee. A record of the dosing event will be prepared and kept by the 
clinical site.  
9. STUDY PROCEDURES  
The study will consist of a Screening Period, a Treatment Phase and a Follow -Up Vis it. A table 
with the Schedule of Events (SOE) representing the required testing procedures to be performed is 
included in Section 1 . Following is a list of these procedures and assessments:  
9.1. Screening Procedures  
Subjects will complete the screening visit within 2 8 days (Day -28 to Day -1) of admission to the 
in-clinic visit of the Treatment  Phase  (Day -1). Prior to conducting any study- related activities  
including screening procedures , written I nformed Consent and the Health Insurance Porta bility and 
Accountability Act (HIPAA) authorization must be  signed and dated by the subject.  
The following information collection/assessments will be performed at the Screening Visit:  
1. Informed Consent  and HIPAA authorization  by the subject . 
2. Subject demographics including date of birth, sex, race, and ethnicity.  
3. Review of  inclusion/exclusion criteria to determine study  eligibility . 
4. Record medical  history  including skin type assessment, chronic conditions, relevant 
surgical procedures (with start date)  history of alcohol and  recreational drug use , 
smoking status,  evaluation of drug and alcohol use  and personal habits affecting the 
skin (example: tanning, hair removal, and application of tattoos). 
5. Fitzpatrick skin type score: Type I - a lways burns, never tans , Type II - usually burns, 
tans with difficulty , or Type III - may burn initially, but tans easily . 
6. A complete physical  exam ination  with back evaluation  and personal habits affecting the 
skin (example: tanning, hair removal, and appl ication of tattoos).  
7. Body weight, height, and BMI. 
8. Vital signs after a minimum of 3  minutes of rest (respiratory rate, pulse  rate, blood 
pressure, and oral temperature). 
9. 12-lead electrocardiogram  (ECG)  after subject  has been  in supine position for  a 
minimu m of 3 minutes . Abnormal ECGs may be repeated for confirmation in which 
case only the repeated ECG will be recorded. The QT interval corrected for heart rate 
will be calculated with Fridericia’s formula (QTcF).  
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 43 of 78  October 2 6, 2020 
 10. Clinical laboratory  tests (chemistry, hematology , coagulation,  and urinalysis ) obtained 
under fasted conditions. During the Screening Period, Clinical Laboratory 
Measurements may be repeated at the discretion of the Investigator. 
11. Blood samples for  Serology (HIV  antibody, hepatitis B  surface antigen and hepatitis C  
virus antibody). 
12. Urine samples will be tested for alcohol, drugs of abuse (amphetamines, 
methamphetamines, benzodiazepines, barbiturates, cannabinoids, cocaine, and opioids ) 
If the test is positive for any of the tested analytes, the subject will be excluded from 
study participation. 
13. Coronavirus (COVID -19) test.  A diagnostic test to determine if an active coronavirus 
infection is present . 
14. A  s e r u m  β -hCG pregnancy test will be performed. A positive pregnancy test will 
exclude a subject from enrollment into the study. 
15. Perform the  Columbia Suicide Severity Rating Scale (C -SSRS), “Baseline” version . 
Subjects with a history of attempted suicide or clinically significant suicidal ideation 
based on the C -SSRS assessment, in the opinion of the Investigator, will be excluded 
from enrollment in the study, and further evaluation and/or preventive intervention steps for suicidal behavior will be taken, at the discretion of the Investigator. 
16. Review of concomitant medications, treatment  and/or therapies .  
After subject s complete  the s creening procedures and are  considered eligible to take part in the 
clinical study , they will be instructed to return to the clinic to begin the Treatment Phase . 
9.2. Check -In Procedures (Day -1) 
Subjects who mee t the inclusion/exclusion criteria during Screening, will be checked into the 
research clinic on Day - 1, the day  before treatment with study drug.  Subjects will undergo the 
following procedures  upon check- in: 
1. Review of inclusion/exclus ion criteria to determine whether subjects continue to meet 
study eligibility.  
2. Update medical history . 
3. Back application site evaluation  and clip application site hair as needed. 
 
4. Vital signs after a minimum of 3  minutes of rest (respiratory rate, pulse  rate, blood 
pressure, and oral temperature). Vital signs will be taken  at least  12 hours prior to the 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 44 of 78  October 2 6, 2020 
 subject receiving their first dose of study drug on Day 1. 
5. 12-lead electrocardiogram (ECG) after subject has been in supine position for a 
minimum of 3 minutes. Abnormal ECGs may be repeated for confirmation in which 
case only the repeated ECG will be recorded. The QT interval corrected for heart rate 
will be calculated with Fridericia’s formula (QTcF ). 
6. Perform the Columbia Suicide Severity Rating Scale (C -SSRS ) “Since Last Visit ” 
version . Subjects with clinically significant suicidal ideation based on the C -SSRS 
assessment, in the opinion of the Investigator,  will be excluded from further participation 
in the study , and further evaluation and/or preventive intervention steps for suicidal 
behavior will be taken, at the discretion of the Investigator. 
7. Clinical laboratory tests (chemistry, hematology, coagulation, and urinalysis) will be 
obtained. 
8. Urine samples wi ll be tested for  alcohol, c otinine, drugs of abuse: (amphetamines, 
methamphetamines, benzodiazepines, barbiturates, cannabinoids, cocaine, and opioids) 
If the test is positive  for any of the tested an alytes, the subject will be excluded from 
study particip ation. 
9. Coronavirus (COVID -19) test.  A diagnostic test to determine if an active coronavirus 
infection is present .   If the test is for the virus is detected , the subject will be excluded 
from study participation  
10. A urine pregnancy test will be performed . A positive pregnancy test will exclude a 
subject from enrollment into the study.   
11. Review of concomitant medications, treatment and/or therapies.  
 
9.3. In-Clinic Procedures Treatment Phase  
Subjects will stay in the research clinic during the  Treatment Phase  for 109 days (108 overnight 
stays)  starting on Day -1. The Treatment Phase  will consist of  3 treatment periods of 36 days each, 
and a 5 ±2 day Follow- Up Visit .  Subjects will be discharged from  the clinical unit on Day 109. 
9.3.1.  Study Drug Administration   
On Day 1  of Period 1 during the  Treatment Phase , subjects will receive  the following treatment : 
Treatment A (Test):  5 mg/day Donepezil TDS manufactured with the commercial process applied 
week ly (within ±1 hour of application time on Day 1) for 5 consecutive weeks (7- day wear each). 
All subjects will receive Treatment A in Period 1. The patch will be removed on the morning of 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 45 of 78  October 2 6, 2020 
 Day 36. 
At the start of Period 2, subjects will be randomized to one of the following treatments in Period 2. 
Subjects will receive the alternate treatment in Period 3. Randomization to the 2 treatment 
sequences will be stratified by gender.   
Treatment B (Test):  10 mg/day Corplex™ Donepezil TDS manufactured with the commercial 
process applied weekly (within ±1 hour of application time on Day 1) for 5 consecutive weeks (7-
day wear each).  
Treatment C (Reference):  10 mg Aricept® donepezil (1 x 10 mg/day tablet) administered QD for 
35 consecutive days (within ±1 hour of dosing time on Day 1). This is the Reference Listed Drug (RLD).  
In each period wherein the treatment consists of a patch, the subjects will wear a total of 5 patches 
for a total of 35 days (5 weeks). The last (5th) patch in the period will be removed after the morning 
blood draw on Day 36 ( 168-hour time point). No treatment will be administered on Day 36 of the 
period; additional post -wear PK blood samples will be collected on Day 36 after any patch 
treatment.  
In each period wherein the treatment consists of  oral Aricept
®, the subjects will an oral dose daily 
for a total of 35 days (5 weeks). The last oral dose in the period will be administered on the morning 
of Day 35. No treatment will be administered on Day 36 of the period; a PK blood sample will be collected in the morning of Day 36 at 24 hours after the last oral dose. In Periods 2 and 3, subjects 
will either wear patches (Treatment B) or receive once- per-day oral Aricept
® (Treatment C).  
• The treatment in Period 2 will start on the morning of Study Day 37 after the pre- dose blood 
draw for Period 2 is collected. No treatment will be administered on Study Day 72. For the patch treatment in Period 2, the patch will be removed on Study Day 72 after the 168 -hour 
blood sample collection.  
• The treatment in Perio d 3 will start on the morning of Study Day 73 after the pre -dose blood 
draw for Period 3 is collected. No treatment will be administered on Study Day 108. For the 
patch treatment in Period 3, the patch will be removed on Study Day 108 after the 168-hour 
blood sample collection. 
TDS Administration (Treatments A and B): 
• The pharmacy at the CRU will remove the TDS from refrigerated storage ( 2-8ºC) and place 
at room temperature storage (20-25ºC) on the day before application, no more than 24 hours 
prior to application.  
• The pharmacy at the CRU will prepare the Corplex™ Donepezil TDS for each subject (per 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 46 of 78  October 2 6, 2020 
 the randomization and stratification scheme). Each TDS treatment will be applied to intact 
dry skin only on the subject’s bac k weekly for 5 consecutive weeks. The most ideal naïve 
location on the back (back area that avoids the bra area and is slightly above the waistline is 
preferred) should be reserved for the last TDS application. If this is not possible Sponsor 
approval should be obtained and documented to apply the TDS to a previously used site. 
• It is recommended that the TDS is applied to the subject within 120 minutes of opening/removing from the packaging. 
• Subjects will be instructed to shower from 1 to 2 hours prior to e ach TDS application. No 
more than 1 shower a day is permitted and if showers are not taken, the following will be 
performed within 1 to 2 hours prior to each TDS application, the application area will be 
washed with room temperature water using a wet washc loth. The application site will be 
patted dry and will be checked for irritancy.  
• The application area will be identified with a template overlay. The TDS will be placed at the designated application site and firm pressure will be applied immediately over the TDS for approximately 20 seconds using the palm of the hand on each TDS to ensure adhesion. A new TDS should not be applied to an area of skin where a TDS was just removed. The area selected should not be oily, damaged, or irritated and should not be e xposed to sunlight.  
• No taping of the transdermal delivery systems will be allowed. 
• The exact clock time of TDS application and removal will be recorded for the start and end 
of TDS application. During each TDS treatment, the next TDS will be applied as soo n as 
the previous TDS was removed. The change in TDSs should be performed within 15 
minutes.  
Oral Drug Administration (Treatment C):  
Study drug will be given orally and be administered with approximately 240 mL of water. Subjects 
will be instructed not to crush, split, or chew the study drug tablets  
The pharmacy manual will provide further application information. 
9.3.2.  Procedures on Dosing  Days (Day s 1, 8, 15, 22, & 29) during Period 1  
The following assessments  will be performed on dosing days during Period 1 of Treatment Phase: 
1. Subjects will be instructed to shower from 1 to 2 hours prior to each TDS application.  I f 
showers are not taken, the following will be performed within 1 to 2 hours prior to each 
TDS application, the application area will be washed with room temperature water using a 
wet washcloth. The application site will be patted dry and will be checked for irritancy.  
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 47 of 78  October 2 6, 2020 
 2. Subjects will receive a light meal approximately 30 minutes prior to TDS application  or oral 
Aricept administration.  
3. Vital signs after a minimum of 3  minutes of rest (respiratory rate, pulse  rate, blood pressure, 
oral temperature) will be collected at times listed in Section 1 3.4. 
4. Blood samples for pharmacokinetics will be collected at times listed in Section 1 4.1. 
5. The site receiving the TDS should be assessed for skin irritation prior to TDS application 
(if the score is greater than zero another site must be selected ). 
6. The TDS is applied to the subject within 120 minutes of opening/removing from the 
packaging  and the application area will be identified with a template overlay. The TDS will 
be placed at the designated application site and firm pressure will be applied immediately 
over the TDS for approximately 20 seconds using the palm of the hand on each TDS to 
ensure ad hesion. The area selected should not be oily, damaged, or irritated and should not 
be exposed to sunlight .  The exact clock time of TDS application will be recorded for the 
start of TDS application.  No taping of the Transdermal Delivery Systems will be al lowed . 
7. A photograph of the TDS will be taken immediately after application  and at all adhesion 
timepoints.  
8. Patch Adhesion Assessments will be performed at times listed in Section 15.1 . 
9. Review of concomitant medications, treatment and/or therapies.  
10. Assessme nt of adverse events . While subjects are in the research clinic,  AEs will be 
monitored continuously and solicited using a non -leading question  at times listed in Section 
13.8. The inquiry using non -leading questions will be performed after all other procedures 
are conducted for the specified time points. 
The PK samples will be collected at the nominal time points ±5 minutes.   
9.3.3.  Procedures for In -Clinic  Days  during Period 1  
The following assessments will be performed during the in -clinic days of  period  1: 
1. Blood samples for pharmacokinetics will be collected at times listed in Section 1 4.1. 
2. TDS  Adhesion Assessments will be performed at times listed in Section 15.0.  
3. A photograph of the TDS will be taken at adhesion timepoints. 
4. Review of concomitant medications, treatment and/or therapies  
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 48 of 78  October 2 6, 2020 
 5. Assessment of adverse events. While subjects are in the research clinic, AEs will be 
monitored continuously and solicited using a non -leading question  at times listed in Section 
13.8. The inquiry using no n-leading questions will be performed after all other procedures 
are conducted for the specified time points. 
9.4. Procedures on  TDS Removal Days (Days 8, 15, 22, 29  & 36 ) during Period 1  
1. Vital signs after a minimum of 3 minutes of rest (respiratory rate, pulse  rate, blood pressure, 
oral temperature) will be collected at times listed in Section 1 3.4. 
2. Immediately after removal, used TDSs will be collected and returned to the Sponsor. As soon as the TDS has been removed from the skin, the used TDS will be placed, adhesive side down, on to a new release liner or folded in half and placed into a foil pouch. The 
sealed, labeled foil pouch and the corresponding original labeled patch pouch will then be 
inserted into a plastic bag and stored at approximately - 20°C ( -4°F) The used TDS will be 
shipped to the Sponsor, for residual drug determination. Additional instructions regarding application and removal of the TDS are provided in the Pharmacy Manual.  
3. TDS site  Irritation Assessments will be obtained at times listed in Section 16.1 . 
4. Blood samples for pharmacokinetics will be collected at times listed in Section 1 4.1. 
5. Obtain blood sample for chemistry, hematology, coagulation, and urinalysis tests.  (Day 36) . 
6. Urine pregnancy tests for females only (Day 36). 
 
7. Perform the Columbia Suicide Severity Rating Scale (C -SSRS) “Since Last Visit” version. 
Subjects with clinically significant suicidal ideation based on the C- SSRS assessment, in 
the opinion of the Investigator, will be excluded from further participation in the study,  
and further evaluation and/or preventive intervention steps for suicidal behavior will be taken, at the discretion of the Investigator (Day 36).  
 
8. Patch Adhesion Assessments and photographs will be performed at times listed in Section 
15.0 
9. Review of concom itant medications, treatment and/or therapies  
10. Assessment of adverse events. While subjects are in the research clinic, AEs will be 
monitored continuously and solicited using a non -leading question at times listed in Section 
13.8.  The inquiry using non -leading questions will be performed after all other procedures 
are conducted for the specified time points.  
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 49 of 78  October 2 6, 2020 
 9.4.1.  Study Drug Administration  (Period 2 & 3) Treatment B  
The following assessments will be performed on dosing days during Period 2 & 3 of Treatment B 
Phase  (Study Days 37, 44, 51, 58, 65 , 73, 80, 87, 94, & 101 ): 
1. Subjects will be instructed to shower from 1 to 2 hours prior to each TDS application.  If showers are not taken, the following will be performed within 1 to 2 hours prior to each TDS application, the application area will be washed with room temperature w ater using a 
wet washcloth. The application site will be patted dry and will be checked for irritancy.  
2. Subjects will receive a light meal approximately 30 minutes prior to TDS application 
3. Vital signs after a minimum of 3 minutes of rest (respiratory rate,  pulse rate, blood pressure, 
oral temperature) will be collected at times listed in Section 1 3.4. 
4. Blood samples for pharmacokinetics will be collected at times listed in Section 1 4.1. 
5. The site receiving the TDS should be assessed for skin irritation prior to TDS application 
(if the score is greater than zero another site must be selected).  
6. The TDS is applied to the subject within 120 minutes of opening/removing from the packaging and the application area will be identified with a template overlay. The TDS w ill 
be placed at the designated application site and firm pressure will be applied immediately over the TDS for approximately 20 seconds using the palm of the hand on each TDS to ensure adhesion. The area selected should not be oily, damaged, or irritated and should not be exposed to sunlight.  The exact clock time of TDS application will be recorded for the 
start of TDS application.  No taping of the Transdermal Delivery Systems will be allowed.  
7. A photograph of the TDS will be taken immediately after appli cation and at adhesion 
timepoints  listed in Section 15.0.  
8. Patch Adhesion Assessments will be performed at times listed in Section 15. 0 
9. Review of concomitant medications, treatment and/or therapies.  
10. Assessment of adverse events. While subjects are in the research clinic, AEs will be 
monitored continuously and solicited using a non -leading question at times listed in Section 
13.8. The inquiry using non -leading questions will be performed after all other procedures  
are conducted for the specified time points. 
The PK samples will be collected at the nominal time points ±5 minutes.  
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 50 of 78  October 2 6, 2020 
 9.4.2.  Procedures on In -Clinic Days Period 2 & 3 Treatment B & C  
The following assessments will be performed during the in- clinic days of Periods 2 &3:  
1. Blood samples for pharmacokinetics will be collected at times listed in Section 1 4.1. 
2. TDS  Adhesion Assessments will be performed at times listed in Section 15.0 Treatment B 
only.   A photograph of the TDS will be taken at adhesion time points  listed in Secti on 15.0 
Treatment B only  
3. Review of concomitant medications, treatment and/or therapies  
4. Assessment of adverse events. While subjects are in the research clinic, AEs will be 
monitored continuously and solicited using a non -leading question  at times listed in  Section 
13.8. The inquiry using non -leading questions will be performed after all other procedures 
are conducted for the specified time points. 
9.4.3.  Procedures on TDS Removal Day Treatment B Periods 2 & 3 (Days 44, 51, 58, 65, 72, 80, 87, 94, 101, 108): 
1. Vital signs after a minimum of 3 minutes of rest (respiratory rate, pulse rate, blood pressure, 
oral temperature) will be collected at times listed in Section 1 3.4. 
2. Immediately after removal, used TDSs will be collected and returned to the Sponsor. As soon as the TDS has been removed from the skin, the used TDS will be placed, adhesive 
side down, on to a new release liner or folded in half and placed into a foil pouch. The sealed, labeled foil pouch and the corresponding original labeled patch pouch will then be 
inserted into a plastic bag and stored at approximately - 20°C ( -4°F). The used TDS will be 
shipped to the Sponsor, for potential residual drug determination. Additional instructions 
regarding application and removal of the TDS are provided in the Pharmacy Manual. 
3. TDS site  Irritation Assessments will be obtained at times listed in Section  16.0 
4. Blood samples for pharmacokinetics will be collected at times listed in Section 1 4.1. 
5. Obtain blood sample for chemistry, hematology, coagulation, and urinalysis tests. (Day 72).  
6. Urine pregnancy tests for females only (Day 72). 
7. Perform the Columbia Suicide Severity Rating Scale (C -SSRS) “Since Last Visit” version. 
Subjects with clinically significant suicidal ideation based on the C -SSRS assessment, in 
the opinion of the Investigator, will be excluded from further participation in the study, and 
further evaluation and/or preventive intervention steps for suicidal behavior will be taken, at the discretion of the Investigator (Day 72). 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 51 of 78  October 2 6, 2020 
 8. Patch Adhesion Assessments and photographs will be  performed at times listed in Section 
15.0.  
9. Review of concomitant medications, treatment and/or therapies  
10. Assessment of adverse events. While subjects are in the research clinic, AEs will be 
monitored continuously and solicited using a non -leading question at times listed in Section 
13.8. The inquiry using non -leading questions will be performed after all othe r procedures 
are conducted for the specified time points 
9.4.4.  Procedures for Drug Administration Treatment C (Period 2 & 3)  
The following assessments will be performed for drug administration for during Period 2 & 3 ): 
1. Subjects will receive a light meal approxim ately 30 minutes prior to drug administration. 
2. Vital signs after a minimum of 3  minutes of rest (respiratory rate, pulse rate, blood pressure, 
oral temperature) will be collected at times listed in Section 1 3.4. 
3. Blood samples for pharmacokinetics will be c ollected at times listed in Section 1 4.1. 
4. Randomized subjects will receive 10  mg Aricept® donepezil (1 x 10  mg/day tablet) 
administered QD for 35  consecutive days  during either Period 2 or Period 3.  Study drug 
will be given orally and be administered with approximately 240 mL of water. Subjects will 
be instructed not to crush, split, or chew the study drug tablets. 
5. Water will be allowed ad libitum up to 1 hour prior to dose administration. No water maybe consumed for 1-hour prior through 1 hour after dosing (except for water needed to 
administer study drug). After 1 hour following dose administration, subjects may dr ink 
water ad libitum.  
6. Review of concomitant medications, treatment and/or therapies.  
7. Assessment of adverse events. While subjects are in the research clinic,  AEs will be 
monitored continuously and solicited using a non -leading question  at times listed in Section 
13.8. The inquiry using non -leading questions will be performed after all other procedures  
are conducted for the specified time points. 
9.4.5.  End of Treatment  (Day 109) 
The end of the treatment phases of the study  is Day 109 . After a ll procedures during t he Treatment 
Phase are conducted including the collection of the  168-hour blood sample  after the last dose of 
study drug, t he following End-of-Treatment procedures will be conducted: 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 52 of 78  October 2 6, 2020 
 1. Complete physical e xamination . 
2. Body weight.  
3. Clinical laboratory tests (chemistry, hematology , coagulation,  and urinalysis). Samples for 
clinical laboratory tests at the end of treatment can be collected under non -fasted conditions. 
4. Urine  pregnancy test (females only).  
5. Vital signs after a minimum of 3 minutes of rest (r espiratory rate, pulse rate, blood pressure, 
oral temperature) . 
6. 12-lead ECG will be obtained after the subject has been in the supine position for at least 3 
minutes.  
7. Assessment of  the Columbia Suicide Severity Rating Sc ale (C-SSRS ), “Since Last Visit” 
version.  If a subject has a clinically significant suicidal ideation based on the C -SSRS 
assessment, in the opinion of the Investigator,  further evaluation and/or preventive 
intervention steps for suicidal behavior will be taken, at the discretion of the Inve stigator.  
8. Review of concomitant medications, treatment and/or therapies.  
9. Assessment of  adverse events.  
Subjects will be discharged from the research clinic when the Investigator determines that the subjects are medically stable,  and all end -of-treatment procedures are completed . 
9.5. Unscheduled Assessments and Early Termination Visits  
9.5.1.  Unscheduled Assessments  
Unscheduled visits occur at any unplanned subject evaluation during study conduct not specified in the Schedule of Events or overall protocol and will be documented and recorded in the database and listings. Unscheduled assessments during study conduct will be inclusive of, but not limited 
to TDS removals, TDS applications, adhesion assessments, adhesion photographs, and skin 
tolerability assessments . 
9.5.2.  Early Termination (ET)  
Early Termination (ET) from the study is defined as withdrawal during the Treatment Phase after 
at least one dose of study drug is administered. The ET Visit is not required for subjects who 
screen fail before t he administration of the first dose of study drug. 
If possible, subjects who terminate early will complete all study procedures post-dose study drug (including PK sample collections) before starting ET procedures. The following procedures will 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 53 of 78  October 2 6, 2020 
 be performed  at ET visits: 
1. Complete physical examination. 
 
2. Vital signs (respiratory rate, pulse rate, blood pressure, and oral temperature) after subject has been sitting for a minimum of 3 minutes.  
 
3. 12-lead ECG after subject has been in supine position for a minimum of 3 minutes.  
4. Clinical laboratory tests (chemistry, hematology coagulation, and urinalysis). Samples for clinical laboratory tests at Early Termination can be collected under non -fasted 
conditions.  
5. Urine  pregnancy tests (for females only)  
 
6. Assessment of the Columbia Suicide Severity Rating Scale (C -SSRS), “Since Last Visit” 
version. If a subject has a clinically significant suicidal ideation based on the C- SSRS 
assessment, in the opinion of the Investigator, further evaluation and/or preventive intervention steps for suicidal behavior will be taken, at the discretion of the Investigator.  
7. If applicable, perform skin irritation/tolerability assessments, adhesion assessments and adhesion photographs.  
8. Review  of concomitant medications, treatment and/or therapies.  
 
9. Assessment of adverse events. 
Subjects will be discharged from the study clinic when the Investigator determines that the subjects 
are medically stable and, if possible, after all ET procedures are completed.  
At the discretion of the Investigator, ensuring the safety of the subjects, any ET procedures that 
were already performed on the same day as part of the procedures of the current treatment phase, 
do not need to be repeated.  Subjects who withdraw early from the study and complete the above ET procedures will not return for a Follow-Up Visit. Therefore, the ET Visit is the EOS for these subjects. 
9.6. Follow -Up Visit 
Subjects who complete the Treatment Phase will return in 5 ±2 days after the administr ation of the 
last dose of study drug for the Follow -Up Visit . 
The following procedures will be completed during the Follow-U p Visit:  
1. Complete physical examination . 
2. Vital signs after a minimum of 3  minutes of rest (respiratory rate, pulse  rate, blood pressure, 
and oral temperature).  
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 54 of 78  October 2 6, 2020 
 3. 12-lead ECG after the subject has been supine at least 3 minutes.  
4. If applicable, perform skin irritation/tolerability assessments.  
5. Review of concomitant medications, treatment and/or therapies.  
6. Assessment of adverse events.  
The Follow- Up Visit is the EOS f or subjects who wi ll undergo the Follow- Up procedures.  
9.7. End of Study (EOS)  
The End of Study (EOS) is either the Follow -Up Visit for subjects who complete the Treatment 
Phase, or the Early Termination Visit for subjects who withdraw early from the study. 
10. CONCOMITANT MEDICATIONS AND RESTRICTIONS  
Subjects will be instructed not to consume any of the below products; however, allowance for an 
isolated single incidental consumption may be evaluated and approved by the study Investigator 
based on the potential for interaction with the study drug, and impact on subject safety and the 
validity of the study results . 
10.1. Concurrent Medication Restrictions  
Restricted Medications:  
1. Any OTC medication use within 14 d ays prior to Day -1 until the End-of-S tudy Visit 
without evaluation and approval by the study Investigator. With approval of the 
Investigator, acetaminophen may be given as needed during the study as rescue 
medication to treat headaches or other adverse events. 
2. Subject must not take any prescription medication, with the exception of female hormonal contraceptives, from 14 days prior to Day -1 until the End -of-Study Visit 
without evaluation and approval by the Investigator. 
All other concomitant me dications will be prohibited unless  its use is deemed necessary in a medical 
emergency. Concomitant use of prescription or nonprescription medications, including reasons for use, will be reviewed,  and recorded on the e CRF from the Screening Period through the Follow -up 
Period.  
Allowed concurrent medications can be taken with water if needed, irrespective of the water restrictions before and after administration of study drug. 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 55 of 78  October 2 6, 2020 
 10.2. Dietary Restrictions  
While subjects are in the research clinic, the following diet ary restrictions will be followed:  
1. Subjects must not take any herbal or dietary supplements (e.g., St. John’s Wort, Milk 
Thistle, etc.) within 14 days prior to Day -1 until the End-of- Study V isit. 
2. Subject s must  not consume beverages and  foods containing alcohol or caffeine/xanthine 
from  48 hours prior to  Day -1 until after discharge on Day 109. Alcohol and caffeinated 
beverages will not be available while in the research clinic. 
3. Water Consumption: Water will be allowed ad libitum up to 1 hour p rior to dose 
administration. For Treatment C (Aricept 10 mg) , after 1 hour following dose 
administration, subjects may drink water ad libitum .  Fluids during the predose light meal 
are allowed.  
4. Food Consumption: While housed in the research clinic, subjec ts will receive meals at 
regularly scheduled times. No food sharing will be permitted.  Standard meals will be 
provided at appropriate times. Calories will be spread across the day. Mealtimes  may be 
adjusted to not interfere with study procedures such as blood draws for pharmacokinetics.  
10.3. General Restrictions  
1. Subject  must  not engage in  strenuous activities such as exercise or sports  within 24 hours 
prior to Day -1 until the End-of-Study V isit. 
2. No more than 1 shower a day is permitted.  Subjects  must avoid having the water spray 
directly on the patch. Water running over the patch is allowed. The patch should be patted dry after the shower . 
3. Subject  must  not donate blood (one pint  or more)  from 30 days or  plasma from  14 days  
prior to Day -1 until the End-of-S tudy Visit. It is recommended  that blood/plasma donations 
not be made for  at least 30 days after  the End-of-Study V isit. 
4. Subjects must not smoke or use  tobacco products from 6 months  prior to Day -1 until the 
End-of-Study Visit.  Subjects must refrain from use of all nicotine products ( including e -
cigarettes, pipes, cigars, chewing tobacco, nicotine topical patches, nicotine gum, or nicotine lozenges ) from Screening until the End -of-Study Visit.  
5. Female subjects must utilize one of  the allowed forms  of birth control  listed  in the Inclusion 
Criteria ( Section 8.2.1 ). 
6. Following all TDS applications, subjects will remain seated in chairs without the following back support: pillows, soft padding, blankets, or similar; for at least the first 2 hours, except 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 56 of 78  October 2 6, 2020 
 when they are supine or standing for study procedures. Subjects wi ll then resume normal 
activity. During the first 2 hours post dose, subjects may be allowed to rise for brief periods 
under supervision (e.g., in order to use the toilet facilities). However, should AEs occur at 
any time, subjects may be placed in an appropriate position or will be permitted to lie down 
on their side . 
7. Following oral drug administration (Treatment C) s ubjects will remain seated, except as 
otherwise required for study procedures or personal needs, for the first 4 hours after dosing. 
Subjects will not be allowed to lie down, except as directed by clinical staff secondary to 
adverse events, for the first 4 hours after dosing. 
11. INVESTIGATIONAL PRODUCT  
11.1. Active Pharmaceutical Ingredients  
Corplex™ Donepezil Transdermal Delivery System (TDS) is a matrix type transdermal patch 
manufactured for a 7 -day application . 
11.2. Pharmaceutical Treatments  
Treatment A (Test):  5 mg/day Donepezil TDS manufactured with the commercial process 
applied weekly (within ±1 hour of application time on Day 1) for 5 consecutive weeks (7 -day 
wear each). All subjects will receive Treatment A in Period 1. The patch will be removed on the 
morning of Day 36.  At the start of Period 2, subjects will be randomized to one of the following treatments in Period 2. Subjects will receive the alt ernate treatment in Period 3. Randomization to the 2 treatment 
sequences will be stratified by gender.  Treatment B (Test): 10 mg/day Corplex™ Donepezil TDS manufactured with the commercial process applied weekly (within ±1 hour of application time on Day 1) for 5 consecutive weeks (7-day wear each).  
 Treatment C (Reference):  10 mg Aricept
® donepezil (1 x 10 mg/day tablet) administered QD 
for 35 consecutive days (within ±1 hour of dosing time on Day 1). This is the Reference Listed Drug (RLD).  
 
11.3. Supply of Study Drug  
The Sponsor (or designee) will ship study drug to the investigational site. The study drug 
shipment(s) will be shipped after s ite activation . All other drug products needed for the conduct of 
the study (such as medications to treat Adverse Events) will be commercially available products 
obtained by the research clinic.  
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 57 of 78  October 2 6, 2020 
 11.4. Packaging and Labeling  
The investigation product  will be pack aged and labeled appropriately, according to the appropriate 
FDA regulations. See the Pharmacy Manual for details of packaging and labeling. 
11.5. Materials Control  
Once received  and labeled by the onsite pharmacist or designee for use in the study, the drugs will 
be considered study drug material. The pharmacist or designee will maintain adequate records of 
the receipt, dispensing, return or other disposition of the drug, including dates, quantity, serial numbers, expiration dates, as appropriate. Reasons for any departure from the expected regimen 
will be documented. These documents will be made available to regulatory agency inspectors upon 
request. The Investigator will not sup ply study drug to anyone other than those named as sub-
investigators on FDA Form 1572, designated site staff, and subjects in the study. 
11.6. Storage of Study Drug 
Study drug for Treatment A and B will be stored at a controlled; refrigerated temperature  (2-8ºC).  
The pharmacy will remove the TDS from 2- 8ºC refrigerated storage on the day before application  
and no more than 24 hours prior to application, and store d at controlled room temperature of 20-
25°C (68- 77°F) with excursions allowed between 15° and 30°C (59° and 86° F). Transient spikes 
up to 40°C are permitted  as long as they do not last for more than 24 hours. Study drug will be 
stored in a safe, secure area with limited, controlled access in accordance with all local, state , and 
federal regulations
.  Investigational products must not be frozen. The Investigator will ensure that 
adequate precautions are taken, including storage of the study drug in a securely locked, substantially constructed cabinet, or other securely locked, substantially constructed encl osure, 
access to which is limited, to prevent theft or diversion of the substance into illegal channels of distribution. 
The investigational product(s) must be stored as indicated. Deviations from the storage 
requirements, including any actions taken, must  be documented and reported to the Sponsor . Once 
a deviation is identified, the investigational product must be quarantined and not used until the 
Sponsor provides documentation of permission to use the investigational product. 
11.7. Study Drug Accountability  
An accurate and current accounting of the dispensing and return of study drug for each subject will 
be maintained on an ongoing basis by a member of the study site staff. The number of study drug dispensed will be recorded on the Investigational Drug Accountability Record. The study monitor 
will verify these documents throughout the course of the study. 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 58 of 78  October 2 6, 2020 
 12. SAFET Y ASSESS MENT  
12.1. Medical History  
A complete medical history will be obtained at the Screening Visit includ ing the recording of 
demographic data ( date of birth, sex, age, race, ethnicity ), collection of previous surgeries, 
medications and chronic conditions, past or present illnesses or dysfunctions, substance/drug abuse, 
and history of allergies or idiosyncratic responses to drugs.  
12.2. Physical Examination  
A complete physical examinat ion including body weight will be completed for all subjects  at 
Screening , at End -of-Treatment  or Early Termination, and at the Follow -Up visits . The complete 
physical examination will in clude a review of the subject’s general appearance, skin, head and neck 
(eyes, ears, nose, mouth, and throat), lymph nodes, thyroid, musculoskeletal/ extremities, 
cardiovascular system, lungs, abdomen and a brief examination of the neurological system. 
Heig ht will be recorded in centimeters (cm) with the subject’s shoes removed. Body weight will be 
measured in kilograms (kg) ; subjects will remain in their normal clothing with shoes and jacket 
(and/or outer clothing) removed. 
12.3. Columbia -Suicide Severity Rating Scale (C -SSRS)  
The Columbia Suicide Severity Rating Scale (C -SSRS) is a brief questionnaire that provides for the 
identification, quantification and standardized assessment of the occurrences and severity of 
suicidal ideation and behavior (see http://cssrs .columbia.edu) (Posner 2011). The typical 
administration time is a few minutes. The “Baseline Version” of the C -SSRS will be assessed at 
Screening. The C -SSRS “Since Last Visit” version will be assessed at  Day -1, Day 36, Day 72, D ay 
109, and Early Termination.  
12.4. Vital Signs  
Vital sign measurements will be obtained after the subject has been seated for 3 minutes. Vital signs 
will include sitting blood pressure (systolic and diastolic measurements), pulse  rate (beats per 
minute), respiratory rate (breat hs per minute), and oral temperature . In order to ensure accuracy, 
out-of- range vital signs may be repeated once, at least 2 minutes  after an abnormal finding. 
Vital signs will be collected at prior to the first dose/application and weekly thereafter.  Tem perature 
checks may be permitted daily . 
12.5. 12-Lead Electrocardiogram  
A 12 -lead electrocardiogram ( ECG ) will be obtained after the subject has been in a supine position 
for a minimum of 3 minutes.  Abnormal ECGs may be repeated for confirmation in which case only 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 59 of 78  October 2 6, 2020 
 the repeated ECG will be reco rded. The QT interval corrected for heart rate will be calculated with 
Fridericia’s formula (QTcF).  
ECGs will be obtained at Screening, Day - 1, ET and EOS visit. 
12.6. Clinical Laboratory Measurements  
All clinical laboratory samples will be sent to a local laboratory for analysis.  Up to approximately  
40 mL of blood will be collected for clinical chemistries, hematology, and pregnancy test (if 
applicable) from each subje ct during the study. During the Screening Period, Clinical Laboratory 
Measurements may be repeated at the discretion of the Investigator. 
The Clinical Laboratory evaluations will consist of the following: 
• Total Hematology as well as differential and Coagulation: red blood cell count, white 
blood cell count with differential (neutrophils, lymphocytes, monocytes, eosinophils, basophils), hemoglob in, hematocrit and platelets,  Prothrombin Time (PT) and  Partial 
Thromboplastin Time (PTT).  
• Serum Chemistry: aspartate aminotransferase  (AST), alanine aminotransferase (ALT), 
albumin, alkaline phosphatase, bicarbonate, total bilirubin, blood urea nitrogen, phosphorus (inorganic) calcium, chloride, creatine phosphokinase, creatinine, gamma 
glutamyl  transferase, glucose, lactate dehydrogenase, potassium, sodium, total protein, 
and uric acid.  
• Urinalysis: microanalysis for specific gravity, pH, protein, glucose, ketones, blood, 
nitrites, leukocytes. If positive  for blood, protein or nitrites , a microsc opic examination 
will be performed.  
• Serology: hepatitis B surface antigen, hepatitis C antibody and human immunodeficiency 
virus antibody.  
• Pregnancy Test s: will be  performed for  all female subject s. A serum β-hCG pregnancy 
test will be performed at Screening. A urine pregnancy test will be performed at check -
in, Day 36, Day 72 , Day 109, and the Early Termination visit, . A positive pregnancy test 
will exclude a subject from enrollment into the study.  A positive urine pregnancy test will 
be confirmed wi th a s erum β-hCG pregnancy test . 
• Urine Screen for Alcohol , Drugs of Abuse : Urine samples will be tested for alcohol, drugs 
of abuse (amphetamines, methamphetamines, benzodiazepines, barbiturates, 
cannabinoids, cocaine, and opioids ) at Screening and at check- in of the Treatment Phase. 
If the test is positive for any of the tested analytes the subject will be excluded from further 
study participation. 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 60 of 78  October 2 6, 2020 
 • Laboratory safety tests will be obtained at the Screening visit, Day -1, Day 36, Day 72, 
Day 109, and at the Early Termination visit. In addition, laboratory safety tests may be 
performed at various unscheduled time points if deemed necessary by the investigator. 
12.7. COVID -19 Testing  
Subjects must have a negative COVID -19 viral test at Screening and Day - 1 in order t o be eligible 
for enrollment.  COVID -19 testing will be performed weekly while subjects are housed in the clinic. 
Other reasons for testing could include but are not limited to : 
• If a subject displays COVID-19 symptoms (fever, cough, loss of taste or smell, or 
diarrhea).  
• If any subject is suspected of coming in contact with a confirmed COVID-19 positive person. 
• At the discretion of the Principle Investigator/in consultation with the Medical Monitor.  
A detailed site COVI D-19 Continuity Plan could be provided to include guidance for testing 
frequency and related safety precautions. 
12.8. Adverse Event Assessments  
Adverse events (AEs) shall be monitored continuously from the administration of the first dose of 
study drug until ei ther the Follow -Up or Early Termination visits  as noted on the Schedule of 
Events .  AEs will be monitored continuously and solicited using a non -leading question  
immediately after dosing  and at 1, 3, 5, 10 , 24 hours post-dose , after all other procedures at  each 
specified time are performed. Definitions and details of AE rep orting and documentation are listed 
in Section  19. 
13. PHARMACOKINETIC ASSESSMENTS  
13.1. Pharmacokinetic Plasma Sample Collection  
Pharmacokinetic Sampling for Treatments A and B  (T
 DS application) : 
The blood PK samples will be collected at the nominal time points listed below ±5 minutes for the 
first 24  hours and 10 minutes thereafter . 
The following blood PK samples will be collected in 2 mL EDTA K2 lavender top tubes : 
• Week  1 (Days 1 to 7): Pre- TDS  #1 application (Day 1), and at 2, 6, 12, 24, 48, 72, 96, 
120, and 144 h after TDS #1 application. 
• Week 2 (Days 8 to 14): Pre-TDS #2 application (Day 8 at 168 h after TDS #1 
application), and at 24, 48, 72, 96, 120, and 144 h a fter TDS  #2 application. 
• Week 3 (Day 15 to 21): Pre-TDS #3 application (Day 15 at 168 h after TDS #2 
application). 
• Week 4 (Day 22 to 28): Pre-TDS #4 application (Day 22 at 168 h after TDS #3 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 61 of 78  October 2 6, 2020 
 application). 
The following blood PK samples will be collected in  4 mL EDTA K2 lavender top tubes: 
• Week 5 (Day 29 to 35): Pre-TDS #5 application (Day 29 at 168 h after TDS #4 
application), and at 3, 6, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, and 156 h after TDS #5 application 
• Week 6 (Day 36): Pre -TDS #5 remo val (Day 36 at 168 h after TDS #5 application), and at 
2, 6, 8, 10, and 12 h after TDS #5 removal. 
The 168 -h post -dose PK blood samples will be collected before removal of the worn TDS.  
Pharmacokinetic Sampling for Treatment C (oral dosing): 
The blood PK s amples will be collected at the nominal time points listed below ±5 minutes for the 
first 24  hours and 10 minutes thereafter . 
The following blood PK samples will be collected in 2 mL EDTA K2 lavender top tubes : 
• Week 1, Day 1: Pre-Dose, and at 1, 2, 3, 4, 6, 8, 12 and 24 h after oral administration (before Day 2 oral administration) 
• Week 2: Day 8 Pre- Dose  
• Week 3: Day 15 Pre- Dose  
• Week 4: Day 22 Pre- Dose  
The following blood PK samples will be collected in 4 mL EDTA K2 lavender top tubes: 
• Week 5: Day 29 Pre- Dose 
• Week 5: Day 35 Pre -Dose, and 1, 2, 3, 4, 6, 8, 12 and 24 h after oral administration (the 24 -
h sample will be collected on Day 36. 
One hundred and four  (104) blood samples will be collected during the entire treatment period. A 
total of approximately 316 mL blood per subject will be drawn for PK analysis. 
Detailed instructions for the collection, processing, storage and shipment of the plasma PK samples 
will be included in the Laboratory Manual. The date and time of collection of each PK sample will be recorded.  
13.2. Pharmacokinetic Sample Shipment  
The plasma samples will be transferred to the analytical laboratory after completion of the study or 
at mutually agreed upon time points during the clinical conduct of the study. Prior to shipment, the 
samples will be appropriately packed in a Styrofoam cooler contai ning dry ice. Sufficient dry ice 
will be added to ensure that the samples will remain frozen for at least 24 hours for local shipments 
and for at least 48  hours for remote shipments. The shipment will be accompanied by documentation 
containing the followin g information: name of the study drug product, protocol number, number of 
patients, and number of samples included in the shipment. 
All frozen PK samples will be transferred with accompanying documentation to: 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 63 of 78  October 2 6, 2020 
 be recorded, and the 0% a dhesion will be assigned to all remaining adhesion time points  of the 
current  wear period . No taping of the TDS will be allowed.  
At each adhesion assessment time point, a photograph will be taken as evidence of the extent of 
TDS adhesion to the skin (as support of the visual observation of the adhesion percentage but not to be used for automated or photometric analysis). 
Following removal of each TDS, the presence or absence of remaining adhesive residue will also 
be recorded.  
14.1. Patch Detachment  
If a TDS partially or fully detaches from the skin, actions to reapply a detached area of the TDS, to apply pressure to the TDS, or to reinforce TDS adhesion with the skin (e.g., taping) must be avoided 
throughout the study. TDS detachment must not be inappropriately inhibited (e.g., by the constant pressure applied by a person or an object such as the back of a chair).  
If a TDS fully detaches from the skin, the TDS must not be reapplied,  and no fresh TDS will be 
applied for the remainder of the intended wear period. The time of full detachment of any TDS and its 0% adherence will be recorded, and the 0% adhesion will be assigned to all remaining adhesion time points of the current wear period . 
15. IRRITATION ASSESSMENTS/SKIN TOLERABILITY 
Dermal response scores, other effects numerical scores, and the combined skin irritation score (calculated as the sum of the dermal response and other effects scores) will be summarized by post removal time po int (0.5, 24, 48, 72 hours post removal). Skin irritation will be followed until skin 
tolerability scores are ≤1. Separate summaries by treatment and by post removal assessment time 
point will be provided. Whole number scores will be used. When evaluating a dermal response, at 
least 25% or more of the patch area should demonstrate an observable response. When multiple 
observable dermal responses are present, each observable response shall represent at least 25% or more of the patch area. It is recommended w hen determining the percentage of patch area with an 
observable response, record each dermal response and determine if each one response represents at least 25% or more of the patch area.  
Skin tolerability assessments will be performed prior to the TDS app lication and after removal of 
the TDS application during each period using the following scale:  
15.1. Tolerability Scales (Dermal Response and Other Effects ) 
Skin Appearance  Score  
No evidence of irritation  0 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 64 of 78  October 2 6, 2020 
 Minimal erythema that is barely perceptible  1 
Definite erythema that is readily visible and minimal edema or 
minimal papular response  2 
Erythema and papules  3 
Definite edema  4 
Erythema, edema, and papules  5 
Vesicular eruption  6 
Strong reaction spreading beyond the application site  7 
 
 Other Effects  
 
Observation  Score 
(Numerical  
Equivalent)  
Slightly glazed appearance  A (0)  
Markedly glazed appearance  B (1)  
Glazing with peeling and cracking  C (2)  
Glazing with fissures  F (3)  
Film of dried serous exudates covering all or 
part of the TDS site G (3)  
Small petechial erosions and/or scabs  H (3)  
Source: FDA Draft Guidance: Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs. 2018. 
16. DISCONTINUATION AND REPLACEMENT OF SUBJECTS  
16.1. Withdrawal of Subjects from the Study  
A subject may be discontinued or  choose to withdraw from study treatment at any time if the subject, 
the Investigator , or the Sponsor feels that it is not in the subject’s best interest to continue. The 
following is a list of possible reasons for study treatment discontinuation:  
• Subject withdrawal of consent. 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 65 of 78  October 2 6, 2020 
 • Subject is not compliant with study procedures. 
• Adverse event that in the opinion of the Investigator would be in the best interest of the 
subject to discontinue study treatment. 
• Protocol violation requiring discontinuation of study treatment . 
• Lost to follow-up. 
• Sponsor request for early termination of the study. 
• Positive pregnancy test (females) . 
• Out-of-range v ital signs , at the discretion of the Investigator. In order to ensure accuracy, 
out-of- range vital signs may be repeated once, at least 2 minutes after an abnormal 
finding. 
• For other reasons (e.g., Investigator/Sponsor request, inappropriate behavior, social reasons ). 
 If a subject is withdrawn from treatment due to an adverse even t, the subject will be followed and 
treated by t he Investigator until the abnormal parameter or symptom has resolved or stabilized. 
All subjects are free to withdraw from participation at any time, for any reason, specified or 
unspecified, and without prejudice. 
16.2. Withd rawal of Subjects Post -Dose Study Drug  
If a subject  meets withdrawal criteria post -dose during the Treatment Phase , the subject will 
complete , if possible, all study procedures  after the current (last ) administration of  study drug  
(including PK sample collections)  before starting Early Termination procedures . The subject will 
be withdrawn  and Early T ermination procedures will be completed prior to the subject’s discharge 
from the clinic.  
At the discretion of the Investigator, ensuring the safety of the subjects, any ET procedures that  
were already performed on the same day as part of the procedures of the current t reatment phase, 
do not need to be repeated.  
The Sponsor may be contacted if clarification is required on a case- by-case basis.  
16.3. Replacement of Subjects  
Treated subjects who d iscontinue treatment or withdraw early from the study will not be  
replaced.  
17. STATISTICAL METHODS  
More details of the statistical analyses will be defined in the Statistical Analysis Plan (SAP). Prior 
to the analysis of the final study data, a detailed SAP will be written describing all analyses that will be performed . 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 66 of 78  October 2 6, 2020 
 17.1. Analysis Populations  
There are 5 populations in this study:  
Randomized Population : all subjects who signed the informed consent form and are assigned a 
randomization number on Day 1 of Treatment Period 1, prior to the first dose of study drug. 
Intent -to-Treat (ITT) Population : all randomized subjects who take a least 1 dose of study drug. 
Demographics and baseline characteristics will be summarized for the ITT population.  
Pharmacokinetic Per-Protocol ( PK-PP) Population : all ITT subjects for a particular treatment  
without any major protocol deviations  that could affect the pharmacokinetic endpoint for that 
particular treatment , who received adequate treatment to reach steady state for done pezil in the 
particular treatment (for example, adequate TDS wear),  and who provide the plasma concentrations 
required to calculate the donepezil AUC 0-168,SS after  a particular treatment . Detailed criteria for the 
PK-PP Population will be listed in the SAP . Demographics and baseline characteristics will be 
summarized for the PK-PP Population by treatment . Data from the PK-PP Population will be used 
for PK data listings, with descriptive statistics, and for statistical comparison between the treatments 
in the Test Products and the Reference . 
Safety Population : all randomized subjects who receive at least one dose of study drug and who 
have at least one safety assessment. Safety measures will be analyzed for all subjects in the Safety 
Population. 
Adhesion Per-Protocol ( ADH -PP) Population:  The ADH -PP population will be based on the 
number of TDSs applied (instead of the number of subjects). All TDSs applied will be part of the 
ADH- PP Population except those that were intentionally removed early in the trial (e.g ., because of 
unacceptable irritation) or from subjects who discontinued use of a  TDS before the end of the 7- day 
wear period for reasons unrelated to adhesion (e.g., because of a protocol violation or an adverse 
event). I ndividual case reports describing any subjects /TDS  who were excluded from the ADH -PP 
Population , and the reasons for their exclusion, will be included in the cl inical study report. The 
ADH- PP Population will be used for the summaries and statistics  of adhesion data. 
17.2. Determination of Sample Size  
An adequate number of subjects (approximately 60 subjects) will be enrolled in the study to plan 
for 48 subjects to complete all study periods. This sample size was based on results of a previous 
steady -state study comparing 10 mg/day  donepezil TDS to oral 10 mg/day  donepezil (Study CL -P-
15086) that showed an AUC geometric mean ratio of 1.04 and a coefficient of variation o f 29.3%. 
The calculated sample size of 48 subjects is estimated to show at least 90% power to assess 
bioequivalence within the limits of 80 to 125% for the geometric mean ratio if the true expected 
geometric mean ratio is 1.05 (assuming a coefficient of va riation of 29%) for AUC . 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 67 of 78  October 2 6, 2020 
 Based on  adhesion scores from previous studies with the  donepezil TDS , the planned sample size 
of the current study should be more than adequate  to demonstrate , based on a one -sided lower 95% 
confidence interval created with 80% power , that > 80% of patches are adhered  for at least 75% 
throughout the wear period. 
17.3. Pharmacokinetic Analysis 
17.3.1.  Pharmacokinetic Parameters  
PK parameters will be calculated for the PP population from plasma concentrations of donepezil 
and 6-O- desmethyl donepezil (active metabolite)  using standard, non- compartmental methods 
using Phoenix® WinNonlin® (Version 8.3 or higher, Certara USA, Inc., Pr inceton, NJ). 
Pharmacokinetic parameters at steady state (Week  5) will include AUC 0-24,SS (daily AUC), AUC 0-
168,SS, Tlag, Cmax, C min, C avg, C trough, C tau, percent peak -to-trough fluctuation (FLUCP). After oral 
administration, AUC 0-24,SS will be calculated and multiplied by 7 to obtain AUC 0-168,SS . In some 
subjects, because of the lag time, the Cmax and Tmax values at steady state may be observed after removal of the TDS (past 168 hours after TDS application). Additional PK parameters will be 
reported (see S AP for details ). 
Area under the plasma concentration versus time curve will be  calculated by the linear trapezoidal 
rule. Concentrations that are below the limit of quantification (BLQ) will be treated as zero in the 
data summarization and descriptive stat istics. In the pharmacokinetic analysis, BLQ concentrations 
will be treated as zero from time  zero up to the time at which the first quantifiable concentration is 
observed; embedded and/or terminal BLQ concentrations will be treated as “missing. 
17.3.2.  Descriptive Statistics for Pharmacokinetics  
For the plasma concentrations at each time point and for each PK parameter, parametric and 
nonparametric descriptive statistics will be calculated. Parametric descriptive statistics include 
number of subjects (n) , arithmetic mean and standard deviation (SD), and percent coefficient of 
variation (%CV). Nonparametric descriptive statistics include minimum, Q1 (25th percentile), median, Q3 (75th percentile), and maximum. Individual plasma concentrations and PK parame ters 
and descriptive statistics by treatment will be listed.  
PK parameters of exposure (concentrations and AUCs) after the 5 mg/day TDS application will be multiplied by 2 to adjust for the lower dose (dose -normalization) before comparison to the 
10 mg/day  treatments.  
17.3.3.  Plasma Concentration -Time Plots  
Individual subject and mean plasma concentration -time profiles will be plotted for donepezil by 
treatment on linear and logarithmic concentration axes . 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 68 of 78  October 2 6, 2020 
 17.3.4.  Statistical PK Comparison between Treatments  
Statistical c omparison of the PK parameters of exposure (AUC 0-24,SS, AUC 0-168,SS, Cmax, Cmin, Ctau, 
percent peak -to-trough fluctuation (FLUCP).) at steady state for donepezil among the 3 treatments 
will be performed using an Analysis of Variance (ANOVA) model for a 3-w ay crossover design on 
the ln -transformed data with sequence, period and treatment as the fixed effects and subject within 
sequence as a random effect. A statistically significant difference is defined as p  <0.05. Intersubject, 
intrasubject and total varia bility (coefficient of variation in percent, CV%) of the PK parameters 
will be reported. 
PK parameters of exposure (concentrations and AUCs) after the 5 mg/day TDS application will be 
multiplied by 2 to adjust for the lower dose (dose -normalization) before  statistical comparison to 
the 10  mg/day treatments.  
17.3.5.  Time to Steady State Assessment  
Assessment of time to achieve steady -state will be performed by a review of weekly donepezil 
trough levels (C tau) at time points immediately prior to dosing on Days 15, 22, 29, and 36 in each 
treatment period. The univariate analysis method described by Chow and Liu for examining when 
steady -state is attained will be implemented using log -transformed trough plasma concentrations.  
Modifications to the method for Treatment Pe riods 2 and 3 will be explained in the SAP,  to possibly 
adjust for the attainment of a new steady state after switching to a new treatment with out a  washout 
period after the previous treatment . 
17.3.6.  Statistical Assessment of Relative Bioavailability 
To examine  the relative bioavailability at steady state of the 5 and 10 mg/day TDS (Tests) relative 
to oral donepezil (Reference), plasma donepezil exposure as characterized by AUC 0-168,SS will be 
assessed and compared utilizing bioequivalence criteria.  The least squares geometric means 
(LSGM) of the PK parameters for each treatment will be reported. Point estimates and 90% Confidence Intervals (CI) for the Test to Reference ratios of geometric means will be provided. 
Similar bioavailability for donepezil will be con cluded if the 90% CIs of the LSGMs lie within the 
acceptable range of 0.80 to 1.25 for AUC
0-168,SS . Forest plots presenting the point estimate and 90% 
confidence intervals for AUC 0-168,SS  will be constructed for the comparisons between the 5  mg/day 
and 10  mg/day donepezil TDS applications (Tests) and oral Aricept® (Reference).  
Since the inten tion of the patch is to decrease the peak -to-through fluctuations with lower C max 
after the patch ap plication compared to daily oral Aricept dosing, rather than using the conventional 
bioequivalence criterion for C max, it is  stipulated that mean steady -state donepezil C max after patch 
administration  should  remain  between the steady -state Cmax and C min after daily oral Aricept® 
administration . 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 69 of 78  October 2 6, 2020 
 17.4. Adhesion Analysis  
TDS adhesion score results (percentage adhesion) for each TDS strength will be summarized 
separately for Weeks 1 through 5 and across all wear periods (Weeks 1 -5 combined) as follows: 
• Summary statis tics (mean, SD, minimum, Q1, median, Q3, maximum) for the mean 
adhesion score, where the mean adhesion score for each patch is the average of the patch 
adhesion scores across the entire wear period.  
• Adhesion score distribution at each adhesion measurement time point post patch application 
(i.e., 12 , 24, …, and 168  hours). 
• Average adhesion score at each adhesion measurement time point post patch application . 
• Number (%) of patches that are completely detached during the 7- day wear period. 
• Number (%) of patches with adhesion <50% at any adhesion measurement time point during 
the 7 -day wear period . 
• Summary of frequency of time a patch was first observed with adhesion <50% during the 7-day wear period . 
• Number (%) of patches with adhesion ≥75% at all adhesion assessment time points  during 
the 7 -day wear period  
To assess whether at least 80% of the TDS applied are at least 75% adhered throughout the 7- day 
wear period, a one -sided 95% confidence interval will be determined for the probability (p) that a 
randomly selected TDS maintains at least 75% adhesion throughout the entire wear period. If the 95% lower confidence limit for p is greater than 80%, acceptable TDS adhesion will be concluded. The method for the calculation of the 95% lower confidence limit and the justification of the method 
will be provided in the SAP. 
To calculate the mean adhesion score and associated statistics, the lowest adhesion score at each 
time point after the baseline time point (t
0) will be carried forward to subsequent time points until a 
lower score is observed.  
17.5. Subject Disposition and Demographic/Baseline Characteristics  
The numbers of subjects screened, the number of subjects randomized overall (Randomized Population) and per treatment sequence group, and the number of subjects in the ITT and PP 
populations overall and by treatment sequence group will be listed. Differences between the number 
of subjects in the analysis populations will be explained. For randomized subjects who discontinue from the study, the primary reason for discontinuation will be listed and summarized by treatment after which they discontinued.  
Summary statistics will be provided by treatment sequence and overall for demographic characteristics (e.g., age, sex, race, and ethnicity) and baseline cha racteristics (e.g., body weight, 
height, BMI) in the ITT and PP populations. Demographic data and baseline characteristics will be 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 70 of 78  October 2 6, 2020 
 compared among treatment sequence groups for the ITT and PP population.  
17.6. Safety Analysis 
All analyses of safety will be conducted on the Safety Population. The safety assessment will be 
based on adverse events, physical exams, vital signs, ECG parameters, C -SSRS, safety laboratory 
tests, and irritation scores (for treatments with TDS).  
Adverse events will be coded in accordance w ith the Medical Dictionary for Regulatory Activities 
(MedDRA). Adverse events with new onset during the study between the initiation of study drug and 5 days after the last dose of study drug will be considered treatment -emergent (TEAEs). This 
will include  any AE with onset prior to initiation of study drug and increased severity after the 
treatment initiation.  
Treatment -emergent adverse events will be summarized by system organ class and preferred term, 
and by treatment. This will include overall incidence  rates (regardless of severity and relationship 
to study drug), and incidence rates for moderate or severe adverse events. A summary of serious adverse events, and adverse events leading to early discontinuation from the study will be presented 
through dat a listings.  
Safety laboratory tests and vital signs will be summarized by post -treatment change from baseline 
for each of the parameters using descriptive statistics by treatment group. Those subjects with 
significant laboratory abnormalities will be ident ified in data listings. Additional safety parameters 
will be summarized in data listings . 
17.7. Interim Analysis  
No interim analysis is planned for this study. 
18. ADVERSE EXPERIENCE REPORTING AND DOCUMENTATIO N 
18.1. Adverse Events  
18.1.1.  Recording and Monitoring of Adverse Even ts 
For the purpose of this clinical trial, all A dverse Events will be recorded and monitored for all 
enrolled subjects from the moment they receive the dose of study drug until they complete the study 
at the EOS (the F ollow -Up visit  or the Early Terminatio n Visit) . 
18.1.2.  Definition  
An adverse event (AE) is any untoward medical occurrence in a clinical investigation of a patient administered a pharmaceutical product and that does not necessarily have a causal relationship with the treatment. An AE is therefore any unfavorable and unintended sign (including an abnormal 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 71 of 78  October 2 6, 2020 
 laboratory finding), symptom or disease temporally associated with the administration of an 
investigational product, whether or not related to that investigational product. An unexpected AE is one of a type not identified in nature, severity, or frequency in the current Investigator’s Brochure 
or of greater severity or frequency than expected based on the information in the Investigator’s Brochure. 
The Investigator or designee will probe, via discussion with the subject, for the occurrence of AEs 
during each subject visit and record the information in the site’s source documents. Adverse events 
will be recorded in the patient CRF. Adverse events will be described by duration (st art and stop 
dates and times), severity, outcome, treatment and relation to study drug, or if unrelated, the cause.  
18.1.3.  AE Grading   
The severity of each AE will be graded by the investigator using the following categories: 
Mild  Does not interfere with subject’ s usual function (awareness of symptoms or signs, but 
easily tolerated [no specific medical intervention required]).  
Moderate  Interferes to some extent with subject’s usual function (enough discomfort to interfere 
with usual activity [minimal intervention ; local intervention; noninvasive 
intervention]).  
Severe  Interferes significantly with subject’s usual function (incapacity to work or to do usual 
activities [significant symptoms requiring hospitalization or invasive intervention]).  
 
If there is a chang e in severity of an AE, only the maximum severity of the AE should be 
recorded.  
The investigator will describe the action taken in the appropriate section of the eCRF, as follows: 
• None 
• Study product stopped 
• Study product temporarily interrupted 
• Concomitant medication  
• Other, specify  
18.1.4.  AE Relationship to Study Drug  
The relationship of an AE to the study drug should be assessed using the following: 
1. Definitely - Previously known toxicity of agent; or an event that follows a reasonable 
temporal sequence  from administration of the drug; that follows a known or expected 
response pattern to the suspected drug; that is confirmed by stopping or reducing the dosage 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 72 of 78  October 2 6, 2020 
 of the drug; and that is not explained by any other reasonable hypothesis. 
2. Probably - An event that follows a reasonable temporal sequence from administration of the 
drug; that follows a known or expected response pattern to the suspected drug; that is 
confirmed by stopping or reducing the dosage of the drug; and that is unlikely to be 
explained by t he known characteristics of the subject’s clinical state or by other 
interventions. 
3. Possibly - An event that follows a reasonable temporal sequence from administration of the 
drug; that follows a known or expected response pattern to that suspected drug; b ut that 
could readily have been produced by a number of other factors.  
4. Unrelated - An event that can be determined with certainty to have no relationship to the 
study drug. 
18.2. Serious A dverse Events 
A Serious Adverse Event ( SAE ) is defined as any AE occurring at any dose that results in any of 
the following  outcomes:  
• Death 
• A life -threatening adverse experience 
• Inpatient hospitalization or prolongation of existing hospitalization 
• A persistent or significant disability/incapacity  
• A congenital anomaly/birth defect 
• Other important medical events may also be considered an SAE when, based on 
appropriate medical judgment, they jeopardize the subject or require intervention to prevent one of the outcomes listed. 
 Other important medical events may also be considered an SAE when, based on appropriate medical 
judgment, they jeopardize the subject or require intervention to prevent one of the outcomes listed. 
Note that AEs of Grade 3 due to hospitalization or prolongation of a hospitalization, and Grade 4 
and Grade 5 per CTCAE grading criteria are classified as SAEs.  
18.2.1.  Serious Adverse Event Reporting  
Within 24 hours after a SAE detection, observation, or report of occurrence (regardless of the  
relationship to test article), the Investigator or designee will enter the SAE into the electronic  
database. The investigator/qualified designee will enter the required information regarding the SAE  
into the appropriate module of the eCRF, which will automatically result in distribution of the  
information to the appropriate sponsor contact. If the EDC system is temporarily unavailable, the  
event, including the investigator -determined causality to study drug, should be reported via a paper  
back -up SAE form to the appropriate sponsor contact. Upon ret urn of the availability of EDC  
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 74 of 78  October 2 6, 2020 
 the alert reports per FDA regulations. 
18.3. Adverse Event Treatment and Follow -up 
All AEs, including SAEs, will be followed to resolution when possible. All AEs and treatment 
administered wil l be recorded on the case report form ( eCRF).  Treatment may be rendered on site 
under the direction of th e Investigator as appropriate. Events requiring diagnostic evaluation or 
treatment beyond the scope of what is available and appropriate within the cli nical research unit 
shall be referred in a timely basis to other care providers. Records of diagnostic and therapeutic interventions shall be requested in compliance with HIPAA requirements, and those received shall be retained in the subject’s file.  
SAE assessment, treatment, and follow up shall be performed up to at least 30 days after last dose 
for events considered definitely, probably, or possibly related to study drug, and continue until 
resolved or clinically stable.  
19. PREGNANCY  
Females with a pos itive pregnancy test will terminate the study early  (Section 10.5). The initial 
report of a pregnancy during the study will be provided to the sponsor within 24 hours of the incident 
identification and to the IRB within a time frame  after  the incident iden tification  as required by the  
IRB.  
All pregnancies will be followed to at least the completion/termination of the pregnancy. The 
Investigator will document the subject visits accordingly  and record the information in the clinical 
site’s source documents. If the pregnancy continues to delivery, the outcome (health of the infant), 
in addition to the maternal health status, must be included in the report. 
Pregnancy will not be considered an AE or SAE ; any pregnancy complication or termination of a 
pregnancy for medical reasons will be recorded as an AE or SAE.  
20. PROTOCOL VIOLATIONS  
A protocol violation occurs when the subject, Investigator, or Sponsor fails to adhere to significant 
protocol requirements that materially (a) reduces the quality or completeness of the data, (b) makes 
the Informed Consent Form inaccurate, or (c) impacts a subject's safety, rights, or welfare. 
Examples of protocol violations may include the following:  
1. Inadequate or delinquent Informed Consent 
2. Inclusion/exclusion criter ia not met 
3. Unreported serious adverse events 
4. Multiple visits missed or outside permissible windows  
5. Materially inadequate record keeping  
6. Intentional deviation from protocol, Good Clinical Practice, or regulations by study 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 75 of 78  October 2 6, 2020 
 personnel 
7. Subject repeated non -comp liance with study requirements  
 
It is the Investigator’s responsibility to report to the IRB of any Protocol Violation(s) according to 
the IRBs policy. Copy of the IRB submission will be filed in the site’s regulatory binder and in the Sponsor’s files.  
21. DAT A MANAGEMENT AND RECORD KEEPING  
21.1. Data Management  
Data will be recorded at the site on CRFs. All entries on a CRF are ultimately the responsibility of 
the Investigator, who is expected to review each form for completeness, accuracy and legibility 
before sign ing. All forms must be filled out by using black ink. Errors should be lined out but not 
obliterated and the correction inserted, initialed and dated. A CRF must be completed for each participant who has given informed consent. The CRFs and source document s must be made 
available to Sponsor and/or its representatives.  
21.2. Record Keeping  
The Investigator must maintain all documents and records, originals or certified copies of original records, relating to the conduct of this trial, and necessary for the evaluat ion and reconstruction of 
the clinical trial. This documentation includes, but is not limited to protocol, CRFs, AE reports, subject source data (including records of subjects, subject visit logs, clinical observations and findings), correspondence with health authorities and IRB, consent forms, inventory of study 
product, Investigator’s curriculum vitae, monitor visit logs, laboratory reference ranges and 
laboratory certification or quality control procedures and laboratory director curriculum vitae.  
The I nvestigator and affiliated Institution should maintain the trial documents as required by the 
applicable regulations. The Investigator and affiliated Institution should take measures to prevent 
accidental or premature destruction of documents. Clinical tri al documents must be kept in the 
clinical site’s archives indefinitely, unless written authorization is obtained from the Sponsor. 
21.3. Access to Source Data/Documents  
The Investigator and research Institution agree that the Sponsor, their representatives, the IRB, and 
representatives from worldwide regulatory agencies will have the right, both during and after the 
clinical trial, to review and inspect pertinent medical records related to the clinical trial.  
22. QUALITY CONTROL AND QUALITY ASSUR ANCE  
By signing the protocol, the Institution and the Sponsor agree to be responsible for implementing and maintaining quality control and quality assurance systems with written standard operating procedures to ensure that trials are conducted and data are generated, documented, and reported in 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 76 of 78  October 2 6, 2020 
 compliance with the protocol, accepted standards of Good Clinical Practice.  (GCP) , ICH and other 
applicable regulations. 
23. ETHICS AND GOOD CLINICAL PRACTICE COMPLIANCE  
Good Clinical Practice is an international ethical and scientific quality standard for designing, 
conducting, recording, and reporting trials that involve human subjects. Compliance with this standard provides public assurance that the rights, safety, and wellbeing of trial subjects are protected, consistent with the principles that have their origin in the Declaration of Helsinki, and 
that the clinical trial data are credible. In this study, the 2008 version of the Declaration of Helsinki 
will be adhered to. It can be found on the website of The World Medical  Association: 
http://www.wma.net/en/30publications/10policies/b3/17c.pdf 
24. PUBLICATION POLICY 
Confidentiality, presentation, and publication of manuscripts containing the study data, and patent applicatio ns related to unpublished study- related information and unpublished information given to 
the Investigator by the Sponsor and/or its representatives shall be handled as set forth in a mutual 
written  agreement  between the Sponsor and the Institution. The publication or presentation of any 
study results shall comply with all applicable privacy laws, including, but not limited to, the Health Insurance Portability and Accountability Act of 1996.  
25. FINANCING AND INSURANCE  
25.1. Finances  
Prior to starting the study, the P rincipal Investigator and/or Institution will sign an agreement with 
the Sponsor related to conducting the clinical trial. This agreement will include the financial information agreed upon by the parties.  
25.2. Insurance Compensation  
The Sponsor certifies that i t has taken out a liability insurance policy covering all clinical trials 
under its sponsorship. This insurance policy is in accordance with local laws and requirements. The 
insurance of the Sponsor does not relieve the Investigator and the other collabora tors from 
maintaining their own liability insurance policy. An insurance certificate will be provided to the 
IRB according to regulatory requirements. 
26. COMPLETION OF STUDY  
The end of the study will be at the time of the last subject, last visit. The IRB will be notified about the end of the study according to regulatory requirements. 
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 77 of 78  October 2 6, 2020 
 27. STUDY ADMINISTRATIVE INFORMATION  
27.1. Protocol Amendments  
Any amendments to the study protocol considered to be a substantial amendment will be 
communicated to the Investigator by the Sponsor. All substantial protocol amendments will 
undergo the same review and approval process as the original protocol and may be implemented 
after it has been approved by the IRB, unless immediate implementation of the change is necessary 
for subject s afety. In this case, the situation must be documented and reported to the IRB according 
to all relevant regulatory requirements. 
A protocol amendment is considered to be a substantial amendment if it is likely to affect the safety, 
physical, or mental inte grity of subjects in the study; the scientific value of the study; the conduct 
or management of the study; or the quality or safety of any Investigational Medicinal Product used in the study.  
Any other minor changes to the protocol not considered to be substantial amendments will not need prior approval of the IRB and will be communicated to the Investigator by the Sponsor. 
  
Protocol CL-P-20003 Amendment #1 CONFIDENTIAL  Corium, Inc. 
 
Page 78 of 78  October 2 6, 2020 
 28. REFERENCES  
Aricept® US Prescribing Information. Eisai R&D Management Co., Ltd. Last updated 
2018 
Assessing Adhesion with Transdermal and Topical Delivery Systems for ANDAs. Guidance for 
Industry. Rockville, MD: Food and Drug Administration; Oct 2018. Available at: 
https://www.fda.gov/media/98634/download 
Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems 
for ANDAs Guidance for Industry. Rockville, MD: Food and Drug Administration; Oct 2018. 
Available at https://www.fda.gov/media/117569/download  
Chow SC, Liu JL. 2009. Design and Analysis of Bioavailability and Bioequivalence Studies. 
Chapman & Hall, Boca Raton, FL. Pages 574- 575. 
Corplex™ Donepezil Transdermal Delivery System (donepezil HCl patch). Investigator’s 
Brochure Edition 8.0. Menlo Park, CA: Corium International, Inc; 23 Sep 2020. 
Coyle JT, Price DL, DeLong MR. Alzheimer's dis ease: a disorder of cortical cholinergic 
innervation. Science. 1983;219(4589):1184 -90. 
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new 
equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604 -12. 
Posner K, Brown GK, Stanley B, et al. The Columbia -Sui cide Severity Rating Scale: initial validity 
and internal consistency findings from three multisite studies with adolescents and adults. Am J 
Psychiatry. 2011;168(12):1266- 77. 
 